IT1229517B
(it)
*
|
1989-01-31 |
1991-09-03 |
Bioresearch Spa |
Impiego di acido 5-metiltetraidrofolico, di acido 5 formiltetraidrofolico, e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato adatte ad essere impiegate nella terapia dei disordini depressivi e composizioni farmaceutiche relative.
|
IT1243859B
(it)
*
|
1990-10-23 |
1994-06-28 |
Bioresearch Spa |
Composizioni farmaceutiche comprendenti associazioni fra sali di s-adenosil-l-metionina e acido 5-metil (o 5-formil)-tetraidrofolico per la terapia di complicanze neurologiche negli ammalati di aids.
|
US6429221B1
(en)
*
|
1994-12-30 |
2002-08-06 |
Celgene Corporation |
Substituted imides
|
US5660835A
(en)
*
|
1995-02-24 |
1997-08-26 |
East Carolina University |
Method of treating adenosine depletion
|
US20020032160A1
(en)
*
|
1995-02-24 |
2002-03-14 |
Nyce Jonathan W. |
Compositions & formulations with an epiandrosterone or a ubiquinone & kits & their use for treatment of asthma symptoms & for reducing adenosine/adenosine receptor levels
|
US6858589B2
(en)
|
1996-01-25 |
2005-02-22 |
Pharmacy And Therapeutic Advisory Consultancy Pty Ltd |
Methods of and compositions for potentiating the action of agents active on cell wall sites of the susceptible bacteria
|
CA2243981C
(en)
*
|
1996-01-31 |
2005-09-06 |
South Alabama Medical Science Foundation |
Food and vitamin preparations containing the natural isomer of reduced folates
|
EP0918746B1
(en)
*
|
1996-08-12 |
2003-04-09 |
Celgene Corporation |
Immunotherapeutic agents and their use in the reduction of cytokine levels
|
CH693255A5
(de)
*
|
1997-06-13 |
2003-05-15 |
Eprova Ag |
Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
|
TR200103757T2
(tr)
|
1998-06-15 |
2002-06-21 |
Sepracor Inc. |
Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (-) norsisapridin kullanımı
|
IL140118A0
(en)
|
1998-06-15 |
2002-02-10 |
Sepracor Inc |
Use of optically pure (+) norcisapride for treating apnea, bulimia and other disorders
|
US6974838B2
(en)
*
|
1998-08-24 |
2005-12-13 |
Sepracor Inc. |
Methods of treating or preventing pain using sibutramine metabolites
|
US6476078B2
(en)
*
|
1999-08-11 |
2002-11-05 |
Sepracor, Inc. |
Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
|
US6339106B1
(en)
|
1999-08-11 |
2002-01-15 |
Sepracor, Inc. |
Methods and compositions for the treatment and prevention of sexual dysfunction
|
US6331571B1
(en)
|
1998-08-24 |
2001-12-18 |
Sepracor, Inc. |
Methods of treating and preventing attention deficit disorders
|
WO2000025793A1
(en)
*
|
1998-10-30 |
2000-05-11 |
Merck Patent Gmbh |
Compositions for the treatment and prevention of neurological and pathopsychological diseases
|
US6342533B1
(en)
|
1998-12-01 |
2002-01-29 |
Sepracor, Inc. |
Derivatives of (−)-venlafaxine and methods of preparing and using the same
|
WO2000040172A1
(en)
*
|
1999-01-05 |
2000-07-13 |
East Carolina University |
Composition and formulations and their use as nociceptic, anti-anxiolytic and anabolic agents
|
JP2002538102A
(ja)
|
1999-03-01 |
2002-11-12 |
セプラコア インコーポレーテッド |
光学的に純粋なr(+)オンダンセトロンを使用する無呼吸および無呼吸障害の治療方法
|
US6342496B1
(en)
|
1999-03-01 |
2002-01-29 |
Sepracor Inc. |
Bupropion metabolites and methods of use
|
US6337328B1
(en)
|
1999-03-01 |
2002-01-08 |
Sepracor, Inc. |
Bupropion metabolites and methods of use
|
US6362202B1
(en)
|
1999-03-02 |
2002-03-26 |
Sepracor Inc. |
Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
|
US6353005B1
(en)
|
1999-03-02 |
2002-03-05 |
Sepracor, Inc. |
Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
|
US6428818B1
(en)
|
1999-03-30 |
2002-08-06 |
Purdue Research Foundation |
Tea catechin formulations and processes for making same
|
US6410052B1
(en)
|
1999-03-30 |
2002-06-25 |
Purdue Research Foundation |
Tea catechins in sustained release formulations as cancer specific proliferation inhibitors
|
DK1466889T3
(da)
*
|
1999-04-06 |
2008-09-08 |
Sepracor Inc |
O-Desmethylvenlafaxin-succinat
|
US6951873B1
(en)
|
1999-04-27 |
2005-10-04 |
Pfizer Inc. |
Methods for treating age-related behavioral disorders in companion animals
|
US6399826B1
(en)
|
1999-08-11 |
2002-06-04 |
Sepracor Inc. |
Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
|
ES2393582T3
(es)
*
|
1999-09-03 |
2012-12-26 |
Apbi Holdings, Llc |
Procedimiento de utilización de inhibidores de la recaptación de serotonina selectivos de inicio rápido de acción para el tratamiento de las disfunciones sexuales
|
IL149340A0
(en)
|
1999-11-18 |
2002-11-10 |
Corvas Int Inc |
Nucleic acids encoding endotheliases, endotheliases and uses thereof
|
US7182953B2
(en)
*
|
1999-12-15 |
2007-02-27 |
Celgene Corporation |
Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
|
US7700341B2
(en)
*
|
2000-02-03 |
2010-04-20 |
Dendreon Corporation |
Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
|
NZ521937A
(en)
*
|
2000-03-31 |
2004-08-27 |
Celgene Corp |
Inhibition of cyclooxygenase-2 activity
|
DE10022856A1
(de)
*
|
2000-05-10 |
2001-11-15 |
Basf Ag |
Therapeutische Kombination von Liponsäure und C1-Donoren zur Behandlung von Störungen des Zentralen Nervensystems
|
US7259152B2
(en)
|
2000-06-07 |
2007-08-21 |
Alfa Wasserman, Inc. |
Methods and compositions using sulodexide for the treatment of diabetic nephropathy
|
US20070208087A1
(en)
*
|
2001-11-02 |
2007-09-06 |
Sanders Virginia J |
Compounds, compositions and methods for the treatment of inflammatory diseases
|
WO2002064083A2
(en)
*
|
2000-11-30 |
2002-08-22 |
The Children's Medical Center Corporation |
Synthesis of 3-amino-thalidomide and its enantiomers
|
US20030167524A1
(en)
*
|
2000-12-19 |
2003-09-04 |
Rooijen Gijs Van |
Methods for the production of multimeric protein complexes, and related compositions
|
ATE369330T1
(de)
*
|
2001-02-12 |
2007-08-15 |
Wyeth Corp |
O-desmethyl-venlafaxine succinat salz
|
AU2002305052A1
(en)
|
2001-03-13 |
2002-09-24 |
Corvas International, Inc. |
Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
|
US7172892B2
(en)
|
2001-03-22 |
2007-02-06 |
Dendreon Corporation |
Nucleic acid molecules encoding serine protease CVSP14, the encoded polypeptides and methods based thereon
|
US7105333B2
(en)
|
2001-03-27 |
2006-09-12 |
Deadreon Corporation |
Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
|
US6610887B2
(en)
*
|
2001-04-13 |
2003-08-26 |
Sepracor Inc. |
Methods of preparing didesmethylsibutramine and other sibutramine derivatives
|
AU2002303427A1
(en)
*
|
2001-04-24 |
2002-11-05 |
East Carolina University |
Compositions and formulations with a non-glucocorticoid steroid and/or a ubiquinone and kit for treatment of respiratory and lung disease
|
AU2002303425A1
(en)
*
|
2001-04-24 |
2002-11-05 |
Epigenesis Pharmaceuticals, Inc. |
Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
|
KR20040080940A
(ko)
|
2001-05-14 |
2004-09-20 |
덴드레온 코포레이션 |
트랜스막 세린 프로테아제 10을 암호화하는 핵산 분자,암호화된 폴리펩티드 및 이에 근거한 방법
|
AU2002346065A1
(en)
*
|
2001-07-05 |
2003-01-21 |
Marantech Holding, Llc |
Methods of using electron active compounds for managing conditions afflicting mammals
|
US20030087963A1
(en)
|
2001-09-13 |
2003-05-08 |
Senanayake Chris H. |
Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
|
US20030134794A1
(en)
*
|
2001-11-20 |
2003-07-17 |
Madison Edwin L. |
Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
|
CN1630514A
(zh)
|
2001-12-05 |
2005-06-22 |
贝勒医学院 |
通过调节交感神经紧张性控制骨形成的方法和组合物
|
US20030181416A1
(en)
*
|
2002-01-10 |
2003-09-25 |
Comper Wayne D. |
Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
|
US20040009953A1
(en)
*
|
2002-01-10 |
2004-01-15 |
Comper Wayne D. |
Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
|
JP4583760B2
(ja)
|
2002-02-01 |
2010-11-17 |
ユーロ−セルティーク エス.エイ. |
疼痛の治療に有用な治療薬
|
US7078526B2
(en)
*
|
2002-05-31 |
2006-07-18 |
Transform Pharmaceuticals, Inc. |
CIS-itraconazole crystalline forms and related processes, pharmaceutical compositions and methods
|
US7927613B2
(en)
|
2002-02-15 |
2011-04-19 |
University Of South Florida |
Pharmaceutical co-crystal compositions
|
US7790905B2
(en)
|
2002-02-15 |
2010-09-07 |
Mcneil-Ppc, Inc. |
Pharmaceutical propylene glycol solvate compositions
|
US7446107B2
(en)
*
|
2002-02-15 |
2008-11-04 |
Transform Pharmaceuticals, Inc. |
Crystalline forms of conazoles and methods of making and using the same
|
WO2004078161A1
(en)
|
2003-02-28 |
2004-09-16 |
Transform Pharmaceuticals, Inc. |
Pharmaceutical co-crystal compositions of drugs such as carbamazeptine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
|
US20030224006A1
(en)
|
2002-03-01 |
2003-12-04 |
Zaworotko Michael J. |
Multiple-component solid phases containing at least one active pharmaceutical ingredient
|
US7893101B2
(en)
|
2002-03-20 |
2011-02-22 |
Celgene Corporation |
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
|
US6962940B2
(en)
|
2002-03-20 |
2005-11-08 |
Celgene Corporation |
(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
|
US7205413B2
(en)
*
|
2002-05-03 |
2007-04-17 |
Transform Pharmaceuticals, Inc. |
Solvates and polymorphs of ritonavir and methods of making and using the same
|
US7323479B2
(en)
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
US7393862B2
(en)
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
NZ570777A
(en)
|
2002-05-17 |
2009-04-30 |
Celgene Corp |
Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
|
US7968569B2
(en)
*
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
US20100129363A1
(en)
*
|
2002-05-17 |
2010-05-27 |
Zeldis Jerome B |
Methods and compositions using pde4 inhibitors for the treatment and management of cancers
|
CN103393695A
(zh)
|
2002-05-17 |
2013-11-20 |
细胞基因公司 |
用于治疗和控制多发性骨髓瘤的方法及组合物
|
USRE48890E1
(en)
|
2002-05-17 |
2022-01-11 |
Celgene Corporation |
Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
|
US20040001801A1
(en)
*
|
2002-05-23 |
2004-01-01 |
Corvas International, Inc. |
Conjugates activated by cell surface proteases and therapeutic uses thereof
|
US8829198B2
(en)
*
|
2007-10-31 |
2014-09-09 |
Proteotech Inc |
Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
|
US6995168B2
(en)
*
|
2002-05-31 |
2006-02-07 |
Euro-Celtique S.A. |
Triazaspiro compounds useful for treating or preventing pain
|
US20070059356A1
(en)
*
|
2002-05-31 |
2007-03-15 |
Almarsson Oern |
Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
|
PT1511710E
(pt)
|
2002-05-31 |
2014-02-26 |
Proteotech Inc |
Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson
|
US7405207B2
(en)
*
|
2002-06-17 |
2008-07-29 |
Epigenesis Pharmaceuticals, Inc. |
Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
|
MXPA04012720A
(es)
*
|
2002-06-17 |
2007-03-23 |
Epigenesis Pharmaceuticals Llc |
Formulaciones de deshidroepiandrosterona para nebulizador y metodos para tratar asma o enfermedad pulmonar obstructiva cronica utilizando composiciones de la misma.
|
IL165383A0
(en)
*
|
2002-06-21 |
2006-01-15 |
Transform Pharmaceuticals Inc |
Pharmaceutical compositions with improved dissolution
|
ATE548354T1
(de)
|
2002-07-24 |
2012-03-15 |
Ptc Therapeutics Inc |
Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen
|
DK1543010T3
(da)
|
2002-09-25 |
2007-09-17 |
Euro Celtique Sa |
N-substituerede hydromorphoner og anvendelse deraf
|
WO2004028463A2
(en)
*
|
2002-09-27 |
2004-04-08 |
Bioenvision, Inc. |
Methods and compositions for the treatment of lupus using clofarabine
|
EP1549141A4
(en)
*
|
2002-09-27 |
2008-06-25 |
Bioenvision Inc |
METHOD AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE DISEASES USING CLOFARABIN
|
JP2006507357A
(ja)
*
|
2002-10-11 |
2006-03-02 |
プロテオテック・インコーポレイテッド |
プロシアニジンb2の単離、精製および合成ならびにその使用
|
EP1900369A1
(en)
|
2002-10-15 |
2008-03-19 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
|
JP2006510606A
(ja)
*
|
2002-10-15 |
2006-03-30 |
セルジーン・コーポレーション |
骨髄異形成症候群を治療および管理するための選択的サイトカイン阻害剤の使用方法およびそれを含む組成物
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US7189740B2
(en)
*
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
US8404717B2
(en)
*
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes using lenalidomide
|
US11116782B2
(en)
|
2002-10-15 |
2021-09-14 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US20050203142A1
(en)
*
|
2002-10-24 |
2005-09-15 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
|
US20040087558A1
(en)
*
|
2002-10-24 |
2004-05-06 |
Zeldis Jerome B. |
Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
|
US7776907B2
(en)
*
|
2002-10-31 |
2010-08-17 |
Celgene Corporation |
Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
|
US7563810B2
(en)
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
MXPA05004780A
(es)
|
2002-11-06 |
2005-10-05 |
Celgene Corp |
Metodos y composiciones que usan farmacos inhibidores selectivos de citocina para el tratamiento y el manejo de canceres y otros padecimientos.
|
CA2505003A1
(en)
*
|
2002-11-06 |
2004-05-27 |
Celgene Corporation |
Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
|
NZ540547A
(en)
*
|
2002-11-18 |
2008-03-28 |
Celgene Corp |
Use of compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide for inhibiting TNF-alpha production
|
BR0316256A
(pt)
*
|
2002-11-18 |
2005-10-04 |
Celgene Corp |
Métodos de inibir a produção de tnf-alfa e a atividade de pde4, de tratar ou prevenir uma doença ou um distúrbio, de controlar os nìveis de camp em uma célula e de produzir um composto, composição farmacêutica e composto
|
US7202259B2
(en)
*
|
2002-11-18 |
2007-04-10 |
Euro-Celtique S.A. |
Therapeutic agents useful for treating pain
|
US6864251B2
(en)
|
2002-12-03 |
2005-03-08 |
Vela Pharmaceuticals, Inc. |
Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines
|
WO2004058147A2
(en)
*
|
2002-12-16 |
2004-07-15 |
Halozyme, Inc. |
Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof
|
US7582635B2
(en)
|
2002-12-24 |
2009-09-01 |
Purdue Pharma, L.P. |
Therapeutic agents useful for treating pain
|
US8183290B2
(en)
|
2002-12-30 |
2012-05-22 |
Mcneil-Ppc, Inc. |
Pharmaceutically acceptable propylene glycol solvate of naproxen
|
EP2339328A3
(en)
|
2002-12-30 |
2011-07-13 |
Transform Pharmaceuticals, Inc. |
Pharmaceutical co-crystal compositions of celecoxib
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
US20090123367A1
(en)
*
|
2003-03-05 |
2009-05-14 |
Delfmems |
Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
|
JP4464395B2
(ja)
|
2003-03-05 |
2010-05-19 |
ヘイローザイム インコーポレイテッド |
可溶性ヒアルロニダーゼ糖タンパク質(sHASEGP)、その調製プロセス、使用およびそれを含む薬学的組成物
|
US7871607B2
(en)
*
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
ES2624610T3
(es)
|
2003-04-11 |
2017-07-17 |
Ptc Therapeutics, Inc. |
Compuestos de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades
|
US20040214893A1
(en)
*
|
2003-04-11 |
2004-10-28 |
Matthew Peterson |
Gabapentin compositions
|
US20050239088A1
(en)
*
|
2003-05-16 |
2005-10-27 |
Shepard H M |
Intron fusion proteins, and methods of identifying and using same
|
US7186863B2
(en)
*
|
2003-05-23 |
2007-03-06 |
Transform Pharmaceuticals, Inc. |
Sertraline compositions
|
US20090227647A1
(en)
*
|
2008-03-05 |
2009-09-10 |
Thomas Lake |
Compounds, Compositions and Methods for the Treatment of Islet Amyloid Polypeptide (IAPP) Accumulation in Diabetes
|
US8916598B2
(en)
|
2003-05-30 |
2014-12-23 |
Proteotech Inc |
Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies
|
US20100331380A1
(en)
*
|
2009-06-29 |
2010-12-30 |
Esposito Luke A |
Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies
|
US7438903B2
(en)
*
|
2003-06-06 |
2008-10-21 |
Nbty, Inc. |
Methods and compositions that enhance bioavailability of coenzyme-Q10
|
MY142655A
(en)
|
2003-06-12 |
2010-12-15 |
Euro Celtique Sa |
Therapeutic agents useful for treating pain
|
PL1641775T3
(pl)
*
|
2003-07-03 |
2009-07-31 |
Euro Celtique Sa |
Pochodne 2-pirydynoalkin użyteczne do leczenia bólu
|
US20050009782A1
(en)
*
|
2003-07-09 |
2005-01-13 |
Comper Wayne D. |
Antiviral charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and methods of use thereof
|
CN1826121B
(zh)
*
|
2003-07-23 |
2013-05-29 |
幸讬制药公司 |
苯基与吡啶基衍生物用于制备调控钙离子释放活化钙离子通道的药物的用途
|
KR20080092473A
(ko)
*
|
2003-07-24 |
2008-10-15 |
유로-셀띠끄 소시에떼 아노님 |
통증 치료 또는 예방에 유용한 헤테로아릴-테트라하이드로피페리딜 화합물
|
PL1648878T3
(pl)
*
|
2003-07-24 |
2009-10-30 |
Euro Celtique Sa |
Związki piperydynowe i zawierające je kompozycje farmaceutyczne
|
EP1867644B1
(en)
|
2003-07-24 |
2009-05-20 |
Euro-Celtique S.A. |
Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
|
US20050026882A1
(en)
*
|
2003-07-31 |
2005-02-03 |
Robinson Cynthia B. |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
|
US20050043282A1
(en)
*
|
2003-07-31 |
2005-02-24 |
Robinson Cynthia B. |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
|
US20090297611A1
(en)
*
|
2003-07-31 |
2009-12-03 |
Robinson Cynthia B |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease
|
US20050026848A1
(en)
*
|
2003-07-31 |
2005-02-03 |
Robinson Cynthia B. |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
|
US20090263381A1
(en)
*
|
2003-07-31 |
2009-10-22 |
Robinson Cynthia B |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
|
US20050026881A1
(en)
*
|
2003-07-31 |
2005-02-03 |
Robinson Cynthia B. |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
|
US20050101545A1
(en)
*
|
2003-07-31 |
2005-05-12 |
Robinson Cynthia B. |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
|
US20050026884A1
(en)
*
|
2003-07-31 |
2005-02-03 |
Robinson Cynthia B. |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
|
US20050026880A1
(en)
*
|
2003-07-31 |
2005-02-03 |
Robinson Cynthia B. |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a cromone for treatment of asthma or chronic obstructive pulmonary disease
|
US20090285899A1
(en)
*
|
2003-07-31 |
2009-11-19 |
Robinson Cynthia B |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
|
US20050026890A1
(en)
*
|
2003-07-31 |
2005-02-03 |
Robinson Cynthia B. |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
|
US20090274676A1
(en)
*
|
2003-07-31 |
2009-11-05 |
Robinson Cynthia B |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
|
US20050085430A1
(en)
*
|
2003-07-31 |
2005-04-21 |
Robinson Cynthia B. |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
|
US20090285900A1
(en)
*
|
2003-07-31 |
2009-11-19 |
Robinson Cynthia B |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
|
US20050113318A1
(en)
*
|
2003-07-31 |
2005-05-26 |
Robinson Cynthia B. |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
|
US20050038004A1
(en)
*
|
2003-07-31 |
2005-02-17 |
Robinson Cynthia B. |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
|
US20050026879A1
(en)
*
|
2003-07-31 |
2005-02-03 |
Robinson Cynthia B. |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease
|
US20050026883A1
(en)
*
|
2003-07-31 |
2005-02-03 |
Robinson Cynthia B. |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
|
PT1942106E
(pt)
|
2003-08-01 |
2011-12-22 |
Euro Celtique Sa |
Agentes terapêuticos úteis para o tratamento da dor
|
AU2004263054B2
(en)
*
|
2003-08-12 |
2009-11-26 |
Kyungdong Pharm. Co., Ltd. |
Preparing method for controlled released type tablet tamsulosin HCl and the tablet thereof
|
WO2005020954A2
(en)
*
|
2003-09-03 |
2005-03-10 |
Agi Therapeutics Limited |
Proton pump inhibitor formulations, and methods of preparing and using such formulations
|
UA83504C2
(en)
|
2003-09-04 |
2008-07-25 |
Селджин Корпорейшн |
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
AU2004276251B2
(en)
|
2003-09-22 |
2008-02-07 |
Euro-Celtique S.A. |
Phenyl - carboxamide compounds useful for treating pain
|
EP1664016B9
(en)
*
|
2003-09-22 |
2009-07-08 |
Euro-Celtique S.A. |
Therapeutic agents useful for treating pain
|
US7612096B2
(en)
*
|
2003-10-23 |
2009-11-03 |
Celgene Corporation |
Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
|
US20050113410A1
(en)
*
|
2003-11-03 |
2005-05-26 |
Mark Tawa |
Pharmaceutical salts of zafirlukast
|
ZA200603718B
(en)
|
2003-11-06 |
2007-09-26 |
Celgene Corp |
Methods and compositions using thalidomide for the treatment and management of cancers and other diseases
|
US7470435B2
(en)
*
|
2003-11-17 |
2008-12-30 |
Andrx Pharmaceuticals, Llc |
Extended release venlafaxine formulation
|
EP2065383A1
(en)
|
2003-11-19 |
2009-06-03 |
Signal Pharmaceuticals, Inc. |
Indazole compounds and methods of use thereof as protein kinase inhibitors
|
EP2428516A1
(en)
|
2003-11-19 |
2012-03-14 |
Metabasis Therapeutics, Inc. |
Novel phosphorus-containing thyromimetics
|
EP1727801B1
(en)
*
|
2003-12-30 |
2009-02-18 |
Euro-Celtique S.A. |
Piperazines useful for treating pain
|
EP2292213A1
(en)
|
2004-02-06 |
2011-03-09 |
Cephalon, Inc. |
Compositions comprising a polymorphic form of armodafinil
|
EP1722758A1
(en)
*
|
2004-02-11 |
2006-11-22 |
Athpharma Limited |
Chronotherapeutic compositions and methods of their use
|
PT1720540E
(pt)
|
2004-02-18 |
2008-09-10 |
Gpc Biotech Ag |
Métodos de tratamento de tumores resistentes ou refractários
|
EP1737453A4
(en)
|
2004-03-22 |
2008-11-26 |
Celgene Corp |
METHOD FOR THE USE OF IMMUNOMODULATORY COMPOUNDS AND COMPOSITIONS CONTAINING THEREOF FOR THE TREATMENT AND SUPPLY OF SKIN DISEASES OR DISORDERS
|
WO2005092065A2
(en)
*
|
2004-03-25 |
2005-10-06 |
Transform Pharmaceuticals, Inc. |
Novel tricyclic compounds and related methods of treatment
|
BRPI0418742A
(pt)
*
|
2004-04-14 |
2007-09-11 |
Celgene Corp |
métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de um sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
|
WO2005110085A2
(en)
*
|
2004-04-14 |
2005-11-24 |
Celgene Corporation |
Use of selective cytokine inhibitory drugs in myelodysplastic syndromes
|
WO2005102317A1
(en)
*
|
2004-04-23 |
2005-11-03 |
Celgene Corporation |
Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension
|
US7351739B2
(en)
*
|
2004-04-30 |
2008-04-01 |
Wellgen, Inc. |
Bioactive compounds and methods of uses thereof
|
US7803366B2
(en)
*
|
2004-05-07 |
2010-09-28 |
Nbty, Inc. |
Methods and compositions that enhance bioavailability of coenzyme-Q10
|
AU2005245896A1
(en)
*
|
2004-05-14 |
2005-12-01 |
Receptor Biologix, Inc. |
Cell surface receptor isoforms and methods of identifying and using the same
|
DE602005023986D1
(de)
|
2004-05-28 |
2010-11-18 |
Transform Pharmaceuticals Inc |
Mischkristalle sowie sie enthaltende pharmazeutische zusammensetzungen
|
WO2005120584A2
(en)
*
|
2004-06-03 |
2005-12-22 |
The Trustees Of Columbia University In The City Of New York |
Radiolabeled arylsulfonyl compounds and uses thereof
|
US7803786B2
(en)
*
|
2004-06-17 |
2010-09-28 |
Transform Pharmaceuticals, Inc. |
Pharmaceutical co-crystal compositions and related methods of use
|
WO2006012536A2
(en)
|
2004-07-22 |
2006-02-02 |
Ritter Andrew J |
Methods and compositions for treating lactose intolerance
|
US20060024409A1
(en)
*
|
2004-07-29 |
2006-02-02 |
Everett Laboratories, Inc. |
Compositions and methods for nutrition supplementation
|
US20060024384A1
(en)
*
|
2004-07-29 |
2006-02-02 |
Giordano John A |
Compositions and methods for nutrition supplementation
|
US7642287B2
(en)
*
|
2004-08-06 |
2010-01-05 |
Transform Pharmaceuticals, Inc. |
Statin pharmaceutical compositions and related methods of treatment
|
US20090042979A1
(en)
*
|
2004-08-06 |
2009-02-12 |
Transform Pharmaceuticals Inc. |
Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
|
BRPI0513082A
(pt)
*
|
2004-08-06 |
2008-04-22 |
Transform Pharmaceuticals Inc |
formulações de fenofibrato e métodos de tratamento relacionados
|
EP2433634A3
(en)
|
2004-09-17 |
2012-07-18 |
The Whitehead Institute for Biomedical Research |
Compounds, compositions and methods of inhibiting a-synuclein toxicity
|
AU2005286701A1
(en)
*
|
2004-09-21 |
2006-03-30 |
Synta Pharmaceutical Corp. |
Compounds for inflammation and immune-related uses
|
EP1645276A1
(en)
*
|
2004-10-08 |
2006-04-12 |
Wageningen Centre for Food Sciences |
Treatment of neurodegenerative disorders
|
WO2006050057A2
(en)
*
|
2004-10-28 |
2006-05-11 |
Celgene Corporation |
Methods and compositions using pde4 modulators for treatment and management of central nervous system injury
|
JP4954083B2
(ja)
|
2004-11-18 |
2012-06-13 |
シンタ ファーマスーティカルズ コーポレイション |
Hsp90活性を調節するトリアゾール化合物
|
EP1831235B1
(en)
|
2004-12-16 |
2013-02-20 |
The Regents of The University of California |
Lung-targeted drugs
|
US7560544B2
(en)
|
2004-12-17 |
2009-07-14 |
Anadys Pharmaceuticals, Inc. |
3,5-Disubsitituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof
|
DE602004021404D1
(de)
|
2004-12-23 |
2009-07-16 |
Gpc Biotech Ag |
Quadratsäurederivate mit antiproliferativer Wirkung
|
WO2006073779A1
(en)
*
|
2004-12-30 |
2006-07-13 |
Transform Phamaceuticals, Inc. |
Novel omeprazole forms and related methods
|
EP1846372B1
(en)
|
2005-01-07 |
2014-04-16 |
Synta Pharmaceuticals Corp. |
Compounds for inflammation and immune-related uses
|
NZ590359A
(en)
|
2005-01-25 |
2012-08-31 |
Synta Pharmaceuticals Corp |
Pyrazine compounds for inflammation and immune-related uses
|
ATE534652T1
(de)
|
2005-04-01 |
2011-12-15 |
Univ California |
Phosphono-pent-2-en-1-yl-nukleoside und analoga
|
WO2006130217A2
(en)
*
|
2005-04-01 |
2006-12-07 |
The Regents Of The University Of California |
Substituted phosphate esters of nucleoside phosphonates
|
AU2006242154B2
(en)
|
2005-05-02 |
2011-11-03 |
Cold Spring Harbor Laboratory |
Composition and methods for cancer diagnosis utilizing the mir 17-92 cluster
|
WO2006119510A2
(en)
*
|
2005-05-04 |
2006-11-09 |
Receptor Biologix, Inc. |
Isoforms of receptor for advanced glycation end products (rage) and methods of identifying and using same
|
US20070041944A1
(en)
*
|
2005-05-05 |
2007-02-22 |
The Trustees Of Columbia University In The City Of New York |
Treating tumors by ENH dislocation of ID proteins
|
US20090170769A1
(en)
*
|
2005-05-13 |
2009-07-02 |
Pei Jin |
Cell surface receptor isoforms and methods of identifying and using the same
|
US20060270707A1
(en)
*
|
2005-05-24 |
2006-11-30 |
Zeldis Jerome B |
Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
|
US20100098640A1
(en)
*
|
2005-06-20 |
2010-04-22 |
Cohen Seth M |
Multidentate Pyrone-Derived Chelators for Medicinal Imaging and Chelation
|
US20070054868A1
(en)
*
|
2005-06-20 |
2007-03-08 |
The Trustees Of Columbia University In The City Of New York |
Synergistic polyphenol compounds, compositions thereof, and uses thereof
|
CA2611636C
(en)
*
|
2005-06-21 |
2013-12-10 |
South Alabama Medical Science Foundation |
Methods and compositions containing natural folates for protecting against radiation damage
|
EP1904046A4
(en)
*
|
2005-07-06 |
2008-10-01 |
Sepracor Inc |
COMBINATIONS OF ESZOPICLON AND O-DESMETHYLVENLAFAXINE AND METHOD FOR THE TREATMENT OF MENOPAUSE AND HUMOR FLUCTUATIONS; ANXIETY AND COGNITIVE INTERFERENCE
|
WO2007013929A1
(en)
|
2005-07-22 |
2007-02-01 |
Amgen Inc. |
Aniline sulfonamide derivatives and their uses
|
US20080058282A1
(en)
|
2005-08-30 |
2008-03-06 |
Fallon Joan M |
Use of lactulose in the treatment of autism
|
CA2620085C
(en)
|
2005-08-31 |
2016-07-12 |
Celgene Corporation |
Isoindole-imide compounds and compositions comprising and methods of using the same
|
US20080138295A1
(en)
*
|
2005-09-12 |
2008-06-12 |
Celgene Coporation |
Bechet's disease using cyclopropyl-N-carboxamide
|
US20070066512A1
(en)
|
2005-09-12 |
2007-03-22 |
Dominique Verhelle |
Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
|
US8492428B2
(en)
*
|
2005-09-20 |
2013-07-23 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
WO2007056155A1
(en)
|
2005-11-03 |
2007-05-18 |
Chembridge Research Laboratories, Inc. |
Heterocyclic compounds as tyrosine kinase modulators
|
KR20080082629A
(ko)
*
|
2005-11-10 |
2008-09-11 |
리셉터 바이오로직스 인크 |
간세포 성장인자 인트론 융합 단백질
|
WO2007132293A2
(en)
|
2005-11-10 |
2007-11-22 |
Circ Pharma Research And Development Limited |
Once-daily administration of central nervous system drugs
|
RS52258B
(en)
*
|
2005-11-21 |
2012-10-31 |
Purdue Pharma Lp |
4-OXADIAZOLYL-PIPERIDINE COMPOUNDS AND THEIR USE
|
US8138361B2
(en)
*
|
2005-12-28 |
2012-03-20 |
The Trustees Of The University Of Pennsylvania |
C-10 carbamates of taxanes
|
US20070155791A1
(en)
*
|
2005-12-29 |
2007-07-05 |
Zeldis Jerome B |
Methods for treating cutaneous lupus using aminoisoindoline compounds
|
JP5738516B2
(ja)
|
2005-12-30 |
2015-06-24 |
ゼンサン (シャンハイ) サイエンス アンド テクノロジー リミテッド |
心機能改善のためのニューレグリンの徐放
|
TWI444370B
(zh)
*
|
2006-01-25 |
2014-07-11 |
Synta Pharmaceuticals Corp |
用於發炎及免疫相關用途之噻唑及噻二唑化合物
|
WO2007087442A2
(en)
|
2006-01-25 |
2007-08-02 |
Synta Pharmaceuticals Corp. |
Substituted biaryl compounds for inflammation and immune-related uses
|
AU2007208151B2
(en)
|
2006-01-25 |
2013-04-18 |
Synta Pharmaceuticals Corp. |
Vinyl-phenyl derivatives for inflammation and immune-related uses
|
US20070254926A1
(en)
*
|
2006-01-31 |
2007-11-01 |
Jun Jiang |
Pyridylphenyl compounds for inflammation and immune-related uses
|
US7518017B2
(en)
|
2006-02-17 |
2009-04-14 |
Idexx Laboratories |
Fenicol compounds and methods synthesizing 2-trifluoroacetamido-3-substituted propiophenone compounds
|
CN101404981A
(zh)
*
|
2006-03-13 |
2009-04-08 |
恩希赛弗制药公司 |
治疗舒张性心力衰竭的方法和组合物
|
MX2008011633A
(es)
|
2006-03-13 |
2008-12-16 |
Activx Biosciences Inc |
Aminoquinolonas como inhibidores de gsk-3.
|
MX2008011844A
(es)
*
|
2006-03-13 |
2008-10-02 |
Encysive Pharmaceuticals Inc |
Formulaciones de sitaxsentano de sodio.
|
BRPI0709699A2
(pt)
*
|
2006-03-29 |
2011-07-26 |
Foldrx Pharmaceuticals Inc |
inibiÇço da toxidez da alfa-sinucleina
|
TW200808695A
(en)
*
|
2006-06-08 |
2008-02-16 |
Amgen Inc |
Benzamide derivatives and uses related thereto
|
DE602007008237D1
(de)
*
|
2006-06-08 |
2010-09-16 |
Amgen Inc |
Benzamidderivate und assoziierte verwendungen
|
SG172692A1
(en)
*
|
2006-06-12 |
2011-07-28 |
Symphogen As |
Pan-cell surface receptor- specific therapeutics
|
US20080026061A1
(en)
*
|
2006-06-22 |
2008-01-31 |
Reichwein John F |
Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
|
JP5345527B2
(ja)
|
2006-06-22 |
2013-11-20 |
アナディス ファーマシューティカルズ インク |
プロドラッグである5−アミノ−3−(3’−デオキシ−β−D−リボフラノシル)−チアゾロ[4,5−d]ピリミジン−2,7−ジオン
|
TWI395749B
(zh)
|
2006-06-22 |
2013-05-11 |
Anadys Pharmaceuticals Inc |
吡咯并〔1,2-b〕嗒酮化合物
|
KR20150033726A
(ko)
|
2006-07-05 |
2015-04-01 |
카탈리스트 바이오사이언시즈, 인코포레이티드 |
프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제
|
EP2043603A4
(en)
|
2006-07-11 |
2010-10-27 |
Arubor Corp |
PREVENTION AND THERAPY OF RHINOSINUSITIS WITH PROINFLAMMATORY CYTOKINHERMERS
|
EP2040712B1
(en)
|
2006-07-18 |
2011-03-02 |
Anadys Pharmaceuticals, Inc. |
Carbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines
|
CL2007002218A1
(es)
|
2006-08-03 |
2008-03-14 |
Celgene Corp Soc Organizada Ba |
Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
|
JP2009545581A
(ja)
*
|
2006-08-04 |
2009-12-24 |
エイジーアイ・セラピューティクス・リサーチ・リミテッド |
Mt1受容体、5ht2b受容体及びl型カルシウムチャンネル活性を有する少なくとも1つの状態の治療方法
|
US8063225B2
(en)
|
2006-08-14 |
2011-11-22 |
Chembridge Corporation |
Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
|
US20080038410A1
(en)
*
|
2006-08-18 |
2008-02-14 |
Everett Laboratories, Inc. |
Compositions and methods for nutrition supplementation
|
US9114133B2
(en)
|
2006-08-25 |
2015-08-25 |
U.S. Dept. Of Veterans Affairs |
Method of improving diastolic dysfunction
|
US8877780B2
(en)
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
BRPI0716092A2
(pt)
|
2006-08-30 |
2013-09-17 |
Celgene Corp |
composto ou um sal, solvato, ou estereoisâmero do mesmo, composiÇço farmacÊutica, mÉtodo para tratar, controlar ou prevenir uma doenÇa ou distérbio, e, forma de dosagem de unidade simples.
|
DK2066662T3
(da)
|
2006-09-21 |
2013-01-07 |
Kyorin Seiyaku Kk |
Serinhydrolaseinhibitorer
|
JP5388854B2
(ja)
|
2006-09-26 |
2014-01-15 |
セルジーン コーポレイション |
5−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法
|
US8779154B2
(en)
|
2006-09-26 |
2014-07-15 |
Qinglin Che |
Fused ring compounds for inflammation and immune-related uses
|
JP2010522135A
(ja)
|
2006-10-09 |
2010-07-01 |
チャールストン ラボラトリーズ,インコーポレイテッド |
医薬組成物
|
EP1914234A1
(en)
*
|
2006-10-16 |
2008-04-23 |
GPC Biotech Inc. |
Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
|
DK2076268T3
(da)
|
2006-10-19 |
2013-04-22 |
Genzyme Corp |
Roscovitin til behandling af visse cystiske sygdomme
|
CN101687788A
(zh)
|
2006-10-19 |
2010-03-31 |
奥斯拜客斯制药有限公司 |
取代的吲哚
|
US20100137421A1
(en)
*
|
2006-11-08 |
2010-06-03 |
Emmanuel Theodorakis |
Small molecule therapeutics, synthesis of analogues and derivatives and methods of use
|
EP2086326B1
(en)
|
2006-11-13 |
2014-01-08 |
Synta Pharmaceuticals Corp. |
Cyclohexenyl-aryl compounds for inflammation and immune-related uses
|
WO2008076270A2
(en)
|
2006-12-13 |
2008-06-26 |
Temple University-Of The Commonwealth System Of Higher Education |
Sulfide, sulfoxide and sulfone chalcone analogues, derivatives thereof and therapeutic uses thereof
|
KR20090086115A
(ko)
*
|
2006-12-22 |
2009-08-10 |
엔싸이시브 파마슈티칼즈 인코퍼레이티드 |
C3a 수용체의 조정제 및 이의 사용 방법
|
CA2673586A1
(en)
*
|
2006-12-26 |
2008-07-24 |
Amgen Inc. |
N-cyclohexyl benzamides and benzeneacetamides as inhibitors of 11-beta-hydroxysteroid dehydrogenases
|
KR101227072B1
(ko)
*
|
2007-01-16 |
2013-01-29 |
시오노기세이야쿠가부시키가이샤 |
Orl-1 리간드로서의 헤테로시클릭-치환 피페리딘
|
KR20200123866A
(ko)
|
2007-02-09 |
2020-10-30 |
메타베이시스 테라퓨틱스, 인크. |
글루카곤 수용체의 길항제
|
BRPI0807604A2
(pt)
|
2007-02-21 |
2014-07-22 |
Sepracor Inc |
Composto, composição farmacêutica, e, métodos para tratar, prevenir ou controlar deprressão, dor, ansiedade, e incontiência
|
PT2144604E
(pt)
|
2007-02-28 |
2011-10-19 |
Conatus Pharmaceuticals Inc |
Métodos para o tratamento da hepatite c viral crónica utilizando ro-113-0830
|
WO2008106167A1
(en)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
|
AR065728A1
(es)
|
2007-03-15 |
2009-06-24 |
Auspex Pharmaceuticals Inc |
Fenetilaminas sustituidas con actividad de serotoninergico y/o norepinefrinergico
|
JP2010523554A
(ja)
|
2007-04-04 |
2010-07-15 |
シグモイド・ファーマ・リミテッド |
タクロリムスの医薬組成物
|
ES2963291T3
(es)
|
2007-04-26 |
2024-03-26 |
Sublimity Therapeutics Ltd |
Fabricación de múltiples minicápsulas
|
AU2008246202B2
(en)
|
2007-04-27 |
2011-12-01 |
Purdue Pharma L.P. |
Therapeutic agents useful for treating pain
|
US20090176796A1
(en)
|
2007-04-27 |
2009-07-09 |
Purdue Pharma L. P. |
Trpv1 antagonists including amide substituent and uses thereof
|
US7892776B2
(en)
|
2007-05-04 |
2011-02-22 |
The Regents Of The University Of California |
Screening assay to identify modulators of protein kinase A
|
EP2019101A1
(en)
*
|
2007-07-26 |
2009-01-28 |
GPC Biotech AG |
Pyrazol[3,4-d]pyrimidin-4-one useful as Kinase Inhibitor
|
MX2009012685A
(es)
|
2007-05-31 |
2009-12-14 |
Sepracor Inc |
Cicloalquilaminas sustituidas con fenilo como inhibidores de la reabsorcion de monoamina.
|
EP2581081A3
(en)
|
2007-06-01 |
2013-07-31 |
The Trustees Of Princeton University |
Treatment of viral infections by modulation of host cell metabolic pathways
|
US8415294B2
(en)
*
|
2007-06-05 |
2013-04-09 |
Arizona Board Of Regents |
Cyclodepsipeptides with antineoplastic activity and methods of using to inhibit cancer and microbial growth
|
CN101730467A
(zh)
*
|
2007-07-06 |
2010-06-09 |
努恩治疗学股份有限公司 |
神经病性疼痛的治疗
|
AU2008274941A1
(en)
*
|
2007-07-12 |
2009-01-15 |
Tragara Pharmaceuticals, Inc. |
Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
|
WO2009012263A2
(en)
*
|
2007-07-18 |
2009-01-22 |
The Trustees Of Columbia University In The City Of New York |
Tissue-specific micrornas and compositions and uses thereof
|
WO2009017818A1
(en)
|
2007-08-01 |
2009-02-05 |
Synta Pharmaceuticals Corp. |
Heterocycle-aryl compounds for inflammation and immune-related uses
|
US8349841B2
(en)
|
2007-08-01 |
2013-01-08 |
Synta Pharmaceuticals Corp. |
Vinyl-aryl derivatives for inflammation and immune-related uses
|
US7893045B2
(en)
|
2007-08-07 |
2011-02-22 |
Celgene Corporation |
Methods for treating lymphomas in certain patient populations and screening patients for said therapy
|
CN106279283A
(zh)
|
2007-08-13 |
2017-01-04 |
症变治疗公司 |
新颖的葡糖激酶活化剂
|
WO2009027852A2
(en)
*
|
2007-08-28 |
2009-03-05 |
Agi Therapeutics, P.L.C. |
Methods and compositions for treating gastrointestinal conditions
|
MX2010002449A
(es)
|
2007-08-31 |
2010-09-07 |
Purdue Pharma Lp |
Compuestos de piperidina tipo quinoxalina sustituida y uso de los mismsos.
|
KR101563018B1
(ko)
*
|
2007-09-11 |
2015-10-23 |
교린 세이야꾸 가부시키 가이샤 |
Gsk-3 억제제로서의 시아노아미노퀴놀론 및 테트라졸로아미노퀴놀론
|
JP5373799B2
(ja)
|
2007-09-12 |
2013-12-18 |
杏林製薬株式会社 |
Gsk−3阻害剤としてのスピロ環式アミノキノロン
|
BRPI0817525A2
(pt)
|
2007-09-26 |
2014-11-18 |
Celgene Corp |
Composto, composição farmacêutica, e, metódo de tratamento, controle ou prevenção de uma doença ou distúrbio.
|
US20090264421A1
(en)
*
|
2007-10-05 |
2009-10-22 |
Bible Keith C |
Methods and Compositions for Treating Cancer
|
WO2009052184A2
(en)
*
|
2007-10-16 |
2009-04-23 |
Receptor Biologix, Inc. |
Compositions comprising optimized her1 and her3 multimers and methods of use thereof
|
US20110009463A1
(en)
*
|
2007-10-17 |
2011-01-13 |
Yuri Karl Petersson |
Geranylgeranyl transferase inhibitors and methods of making and using the same
|
EP2200649A4
(en)
|
2007-10-19 |
2012-09-26 |
Univ California |
COMPOSITIONS AND METHODS FOR TREATING CNS INFUSION, PSYCHOSIS, DELIRE, PTSD OR PTSS
|
EP2231596A4
(en)
|
2007-12-14 |
2012-06-06 |
Univ Georgetown |
INHIBITORS OF HISTONATE ACETYLASE
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
EP2240022B1
(en)
|
2008-01-09 |
2016-12-28 |
Charleston Laboratories, Inc. |
Bilayered tablets comprising oxycodone and promethazine
|
TWI395593B
(zh)
|
2008-03-06 |
2013-05-11 |
Halozyme Inc |
可活化的基質降解酵素之活體內暫時性控制
|
US8658163B2
(en)
|
2008-03-13 |
2014-02-25 |
Curemark Llc |
Compositions and use thereof for treating symptoms of preeclampsia
|
DK2947072T3
(en)
|
2008-03-17 |
2017-01-23 |
Ambit Biosciences Corp |
1- (3- (6,7-DIMETHOXYQUINAZOLIN-4-YLOXY) PHENYL) -3- (5- (1,1,1-TRIFLUOR-2-METHYLPROPAN-2-YL) ISOXAZOL-3-YL) UREA AS RAF CHINESE MODULATOR IN TREATMENT OF CANCER DISEASES
|
US9249147B2
(en)
|
2008-03-19 |
2016-02-02 |
Chembridge Corporation |
Tyrosine kinase inhibitors
|
US8822500B2
(en)
|
2008-03-19 |
2014-09-02 |
Chembridge Corporation |
Tyrosine kinase inhibitors
|
AU2009226153B2
(en)
|
2008-03-19 |
2014-02-20 |
Chembridge Corporation |
Novel tyrosine kinase inhibitors
|
EP2687213B1
(en)
|
2008-03-27 |
2019-01-23 |
Celgene Corporation |
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
|
KR20100132045A
(ko)
|
2008-03-27 |
2010-12-16 |
셀진 코포레이션 |
(+)-2-[1-(3-에톡시-4-메톡시페닐)-2-메틸설포닐에틸]-4-아세틸아미노이소인돌린-1,3-디온을 포함하는 고체 형태, 이의 조성물, 및 이의 용도
|
EP2285402A2
(en)
|
2008-04-14 |
2011-02-23 |
Halozyme, Inc. |
Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
|
US8084025B2
(en)
|
2008-04-18 |
2011-12-27 |
Curemark Llc |
Method for the treatment of the symptoms of drug and alcohol addiction
|
EP2112152A1
(en)
|
2008-04-22 |
2009-10-28 |
GPC Biotech AG |
Dihydropteridinones as Plk Inhibitors
|
EP2112150B1
(en)
|
2008-04-22 |
2013-10-16 |
Forma Therapeutics, Inc. |
Improved raf inhibitors
|
US20090298882A1
(en)
*
|
2008-05-13 |
2009-12-03 |
Muller George W |
Thioxoisoindoline compounds and compositions comprising and methods of using the same
|
MX2010012514A
(es)
*
|
2008-05-20 |
2011-05-30 |
Cerenis Therapeutics S A |
Niacina y un medicamento nsaid para tratamiento combinado.
|
WO2009158430A1
(en)
*
|
2008-06-25 |
2009-12-30 |
Iskandar Bermans S |
(6s)-5-methyltetrahydrofolic acid for therapy of tissue injury
|
EP2318035B1
(en)
|
2008-07-01 |
2019-06-12 |
Curemark, Llc |
Methods and compositions for the treatment of symptoms of neurological and mental health disorders
|
BRPI0913677A2
(pt)
|
2008-07-02 |
2015-12-15 |
Idenix Pharmaceuticals Inc |
composto, metabólito purificado, método para tratar um hospedeiro infectado com um vírus flaviviridade, composição farmacêutica, método para preparar o composto purificado, e, processo para preparar o composto
|
WO2010010458A1
(en)
|
2008-07-21 |
2010-01-28 |
Purdue Pharma L.P. |
Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
|
CN103450206A
(zh)
|
2008-07-30 |
2013-12-18 |
普渡制药公司 |
丁丙诺啡类似物
|
PT2799428T
(pt)
|
2008-08-13 |
2017-02-17 |
Metabasis Therapeutics Inc |
Antagonistas de glicagina
|
EP2348863A4
(en)
|
2008-09-04 |
2012-03-07 |
Anacor Pharmaceuticals Inc |
BORN SMALL MOLECULES
|
WO2010031054A1
(en)
|
2008-09-15 |
2010-03-18 |
Biovista, Inc. |
Compositions and methods for treating epilepsy
|
AU2009300317A1
(en)
*
|
2008-10-01 |
2010-04-08 |
Synta Pharmaceuticals Corp. |
Compounds for inflammation and immune-related uses
|
WO2010042834A1
(en)
|
2008-10-09 |
2010-04-15 |
Anadys Pharmaceuticals, Inc. |
A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
|
JP2012505241A
(ja)
*
|
2008-10-10 |
2012-03-01 |
パーデュー・リサーチ・ファウンデーション |
アルツハイマー病の治療用組成物
|
US8546388B2
(en)
*
|
2008-10-24 |
2013-10-01 |
Purdue Pharma L.P. |
Heterocyclic TRPV1 receptor ligands
|
US8759362B2
(en)
*
|
2008-10-24 |
2014-06-24 |
Purdue Pharma L.P. |
Bicycloheteroaryl compounds and their use as TRPV1 ligands
|
US8703962B2
(en)
*
|
2008-10-24 |
2014-04-22 |
Purdue Pharma L.P. |
Monocyclic compounds and their use as TRPV1 ligands
|
NZ592425A
(en)
|
2008-10-29 |
2013-04-26 |
Celgene Corp |
Isoindoline compounds for use in the treatment of cancer
|
EP2376083A4
(en)
*
|
2008-11-20 |
2012-06-20 |
Purdue Research Foundation |
CHINAZOLIN INHIBITORS OF BACE 1 AND METHOD OF USE
|
US8859590B2
(en)
|
2008-12-05 |
2014-10-14 |
Purdue Research Foundation |
Inhibitors of BACE1 and methods for treating Alzheimer's disease
|
DK3037529T3
(da)
|
2008-12-09 |
2019-05-20 |
Halozyme Inc |
Udvidede opløselige ph20-polypeptider og anvendelse deraf
|
CN105384676B
(zh)
|
2008-12-16 |
2019-05-07 |
桑诺维恩药品公司 |
三重再摄取抑制剂及其应用方法
|
US20110306605A1
(en)
|
2008-12-22 |
2011-12-15 |
Sloan-Kettering Institute For Cancer Research |
Coumarin-based compounds for the treatment of alzheimer's disease and cancer
|
EP2379073A2
(en)
|
2008-12-22 |
2011-10-26 |
Sloan Kettering Institute For Cancer Research |
Methods for treating or preventing cancer and neurodegenerative diseases
|
WO2010076329A1
(en)
|
2008-12-31 |
2010-07-08 |
Scynexis, Inc. |
Derivatives of cyclosporin a
|
KR20170005191A
(ko)
|
2009-01-06 |
2017-01-11 |
큐어론 엘엘씨 |
이. 콜라이에 의한 구강 감염의 치료 또는 예방을 위한 조성물 및 방법
|
ES2882518T3
(es)
|
2009-01-06 |
2021-12-02 |
Galenagen Llc |
Composición que comprende proteasa, amilasa y lipasa
|
WO2010088450A2
(en)
|
2009-01-30 |
2010-08-05 |
Celladon Corporation |
Methods for treating diseases associated with the modulation of serca
|
WO2010091268A1
(en)
|
2009-02-09 |
2010-08-12 |
Sepracor Inc. |
Pyrrolidine triple reuptake inhibitors
|
PE20151143A1
(es)
|
2009-02-10 |
2015-08-07 |
Celgene Corp |
Metodos para utilizar y composiciones que comprenden moduladores pde4 para tratamiento, prevencion y control de tuberculosis
|
EP2396312A1
(en)
|
2009-02-11 |
2011-12-21 |
Celgene Corporation |
Isotopologues of lenalidomide
|
KR20110132564A
(ko)
|
2009-02-11 |
2011-12-08 |
선오비온 파마슈티컬스 인코포레이티드 |
히스타민 h3 역 작용제 및 길항제, 및 이의 사용 방법
|
US8568793B2
(en)
|
2009-02-11 |
2013-10-29 |
Hope Medical Enterprises, Inc. |
Sodium nitrite-containing pharmaceutical compositions
|
SG2014014435A
(en)
|
2009-02-24 |
2014-07-30 |
Ritter Pharmaceuticals Inc |
Prebiotic formulations and methods of use
|
CN105837560A
(zh)
|
2009-02-27 |
2016-08-10 |
埃姆比特生物科学公司 |
调控jak激酶的喹唑啉衍生物和其使用方法
|
JP5690286B2
(ja)
|
2009-03-04 |
2015-03-25 |
イデニク プハルマセウティカルス,インコーポレイテッド |
ホスホチオフェン及びホスホチアゾールhcvポリメラーゼ阻害剤
|
US20110229451A2
(en)
*
|
2009-03-06 |
2011-09-22 |
Halozyme, Inc. |
Temperature sensitive mutants of matrix metalloproteases and uses thereof
|
AU2010221990B2
(en)
*
|
2009-03-11 |
2015-06-04 |
Kyorin Pharmaceutical Co., Ltd. |
7-cycloalkylaminoquinolones as GSK-3 inhibitors
|
JP2012520314A
(ja)
|
2009-03-11 |
2012-09-06 |
アムビト ビオスシエンセス コルポラチオン |
癌治療のためのインダゾリルアミノピロロトリアジンとタキサンの併用
|
AR075974A1
(es)
|
2009-03-27 |
2011-05-11 |
Pathway Therapeutics Ltd |
Pirimidinil y 1,3,5-triazinilbencimidazolsulfonamidas y su uso en terapia del cancer
|
WO2010110686A1
(en)
|
2009-03-27 |
2010-09-30 |
Pathway Therapeutics Limited |
Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
|
US9056050B2
(en)
|
2009-04-13 |
2015-06-16 |
Curemark Llc |
Enzyme delivery systems and methods of preparation and use
|
EA201101524A1
(ru)
|
2009-04-20 |
2012-07-30 |
Элселикс Терапьютикс, Инк. |
Способ и композиция для лечения состояния, связанного с хемосенсорным рецептором
|
US8828953B2
(en)
*
|
2009-04-20 |
2014-09-09 |
NaZura BioHealth, Inc. |
Chemosensory receptor ligand-based therapies
|
US9901551B2
(en)
|
2009-04-20 |
2018-02-27 |
Ambra Bioscience Llc |
Chemosensory receptor ligand-based therapies
|
TW201041583A
(en)
|
2009-04-22 |
2010-12-01 |
Axikin Pharmaceuticals Inc |
2,5-disubstituted arylsulfonamide CCR3 antagonists
|
CN102459210B
(zh)
|
2009-04-22 |
2015-09-02 |
埃克希金医药品有限公司 |
芳基磺酰胺ccr3拮抗剂
|
HUE038507T2
(hu)
|
2009-04-22 |
2018-10-29 |
Sma Therapeutics Inc |
2,5-diszubsztituált arilszulfonamid CCR3-antagonisták
|
US9968574B2
(en)
*
|
2009-05-15 |
2018-05-15 |
The University Of Kentucky Research Foundation |
Treatment of MCI and Alzheimer's disease
|
EP2429992A4
(en)
*
|
2009-05-15 |
2012-11-28 |
Univ Kentucky Res Found |
TREATMENT OF EASY COGNITIVE IMMUNITY AND MORBUS ALZHEIMER
|
CA2762179A1
(en)
|
2009-05-18 |
2010-11-25 |
Sigmoid Pharma Limited |
Composition comprising oil drops
|
EP2436387B1
(en)
|
2009-05-25 |
2018-07-25 |
Celgene Corporation |
Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex
|
SG176735A1
(en)
|
2009-06-10 |
2012-01-30 |
Sunovion Pharmaceuticals Inc |
Histamine h3 inverse agonists and antagonists and methods of use thereof
|
US9050276B2
(en)
|
2009-06-16 |
2015-06-09 |
The Trustees Of Columbia University In The City Of New York |
Autism-associated biomarkers and uses thereof
|
WO2011003870A2
(en)
|
2009-07-06 |
2011-01-13 |
Creabilis S.A. |
Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
|
EP2451802A1
(en)
|
2009-07-07 |
2012-05-16 |
Pathway Therapeutics, Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
|
US8496973B2
(en)
|
2009-07-08 |
2013-07-30 |
Hope Medical Enterprises, Inc. |
Sodium thiosulfate-containing pharmaceutical compositions
|
CA2767576C
(en)
|
2009-07-08 |
2020-03-10 |
Charleston Laboratories Inc. |
Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
|
AU2010271178B2
(en)
|
2009-07-10 |
2015-10-22 |
Linzy O. Scott Iii |
Methods and compositions for treating thyroid-related medical conditions with reduced folates
|
EP2467144A1
(en)
|
2009-07-24 |
2012-06-27 |
ViroLogik GmbH |
Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
|
US8404728B2
(en)
|
2009-07-30 |
2013-03-26 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
EP2459184A1
(en)
|
2009-07-31 |
2012-06-06 |
The Brigham and Women's Hospital, Inc. |
Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
|
WO2011017389A1
(en)
|
2009-08-05 |
2011-02-10 |
Idenix Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
|
IN2012DN00781A
(it)
|
2009-08-12 |
2015-06-26 |
Sigmoid Pharma Ltd |
|
BR112012003661A2
(pt)
|
2009-08-19 |
2017-04-25 |
Ambit Biosciences Corp |
"compostos de biarila e métodos de uso dos mesmos."
|
RU2012112943A
(ru)
|
2009-09-04 |
2013-10-10 |
Юнайтед Парагон Эссоушиэйтс Инк. |
Соединения для лечения расстройства или заболевания, связанного с активностью нейрокининового 2 рецептора
|
WO2011031816A2
(en)
|
2009-09-11 |
2011-03-17 |
Sepracor Inc. |
Histamine h3 inverse agonists and antagonists and methods of use thereof
|
WO2011042482A1
(en)
|
2009-10-06 |
2011-04-14 |
Green Molecular |
Polyphenols for use in the treatment of cancer
|
NZ622713A
(en)
|
2009-10-19 |
2015-07-31 |
Synta Pharmaceuticals Corp |
Combination cancer therapy with hsp90 inhibitory compounds
|
WO2011056566A2
(en)
|
2009-10-26 |
2011-05-12 |
Sunesis Pharmaceuticals, Inc. |
Compounds and methods for treatment of cancer
|
EP2325185A1
(en)
|
2009-10-28 |
2011-05-25 |
GPC Biotech AG |
Plk inhibitor
|
WO2011056764A1
(en)
|
2009-11-05 |
2011-05-12 |
Ambit Biosciences Corp. |
Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
|
WO2011063076A1
(en)
|
2009-11-19 |
2011-05-26 |
Itherx Pharmaceuticals, Inc. |
Methods of treating hepatitis c virus with oxoacetamide compounds
|
MX2012004741A
(es)
|
2009-11-19 |
2012-05-22 |
Celgene Corp |
Apremilast para el tratamiento de sarcoidosis.
|
WO2011064769A1
(en)
|
2009-11-24 |
2011-06-03 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Methods and pharmaceutical compositions for the treatment of hot flashes
|
US20110301235A1
(en)
|
2009-12-02 |
2011-12-08 |
Alquest Therapeutics, Inc. |
Organoselenium compounds and uses thereof
|
RU2707067C2
(ru)
|
2009-12-04 |
2019-11-22 |
Суновион Фармасьютикалз, Инк. |
Полициклические соединения и способы их применения
|
MX339619B
(es)
|
2009-12-04 |
2016-06-02 |
Sunovion Pharmaceuticals Inc |
Formulaciones, sales y polimorfos de transnorsertralina y usos de los mismos.
|
EP2509615A1
(en)
|
2009-12-09 |
2012-10-17 |
Scynexis, Inc. |
Novel cyclic peptides
|
MY159958A
(en)
|
2009-12-18 |
2017-02-15 |
Idenix Pharmaceuticals Inc |
5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
|
EP2516395A1
(en)
|
2009-12-22 |
2012-10-31 |
Celgene Corporation |
(methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses
|
SG181896A1
(en)
*
|
2009-12-23 |
2012-07-30 |
Map Pharmaceuticals Inc |
Novel ergoline analogs
|
WO2011082289A1
(en)
|
2009-12-30 |
2011-07-07 |
Scynexis Inc. |
Cyclosporine analogues
|
USRE49251E1
(en)
|
2010-01-04 |
2022-10-18 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
DK3536333T3
(da)
|
2010-01-04 |
2022-10-24 |
Mapi Pharma Ltd |
Depotsystem der omfatter glatirameracetat
|
EP2851070A1
(en)
|
2010-01-05 |
2015-03-25 |
Celgene Corporation |
A combination of lenalidomide and artesunate/artemisone for treating cancer
|
WO2011089167A1
(en)
|
2010-01-19 |
2011-07-28 |
Virologik Gmbh |
Kombination of proteasome inhibitors and anti -hepatitis medication for treating retroviral diseases
|
WO2011094890A1
(en)
|
2010-02-02 |
2011-08-11 |
Argusina Inc. |
Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
|
ES2632548T3
(es)
|
2010-02-05 |
2017-09-14 |
Tragara Pharmaceuticals, Inc. |
Formas de estado sólido de los inhibidores de la quinasa macrocíclica
|
LT3202460T
(lt)
|
2010-02-11 |
2019-10-10 |
Celgene Corporation |
Arilmetoksi izoindolino dariniai ir kompozicijos, apimantys ir jų panaudojimo būdus
|
WO2011100550A2
(en)
*
|
2010-02-12 |
2011-08-18 |
Alexander Vuckovic, M.D., Llc |
Compositions and methods for treating depression
|
AU2011223873B2
(en)
|
2010-03-02 |
2015-06-25 |
Axikin Pharmaceuticals, Inc. |
Isotopically enriched arylsulfonamide CCR3 antagonists
|
WO2011112689A2
(en)
|
2010-03-11 |
2011-09-15 |
Ambit Biosciences Corp. |
Saltz of an indazolylpyrrolotriazine
|
WO2011112933A1
(en)
|
2010-03-12 |
2011-09-15 |
Celgene Corporation |
Methods for the treatment of non-hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor
|
MX336559B
(es)
|
2010-03-17 |
2016-01-25 |
Axikin Pharmaceuticals Inc |
Antagonistas de ccr3 de arilsulfonamida.
|
WO2011116287A1
(en)
|
2010-03-19 |
2011-09-22 |
Purdue Research Foundation |
Ccr5 modulators for treating hiv
|
CA2794096A1
(en)
|
2010-04-07 |
2011-10-13 |
Celgene Corporation |
Methods for treating respiratory viral infection
|
AU2011237592B2
(en)
|
2010-04-08 |
2016-10-27 |
Emory University |
Substituted androst-4-ene diones
|
EP2560640A1
(en)
|
2010-04-19 |
2013-02-27 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
|
WO2011133521A2
(en)
|
2010-04-19 |
2011-10-27 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
|
WO2011137249A1
(en)
|
2010-04-28 |
2011-11-03 |
Ritter Pharmaceuticals, Inc. |
Prebiotic formulations and methods of use
|
WO2011140360A1
(en)
|
2010-05-05 |
2011-11-10 |
The Trustees Of Columbia University In The City Of New York |
Radiolabeled compounds and uses thereof
|
AU2011255438A1
(en)
|
2010-05-20 |
2013-01-10 |
Synta Pharmaceuticals Corp. |
Method of treating lung adenocarcinoma with Hsp90 inhibitory compounds
|
EP2575810A1
(en)
|
2010-05-24 |
2013-04-10 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor
|
NZ603789A
(en)
|
2010-05-26 |
2015-03-27 |
Sunovion Pharmaceuticals Inc |
Heteroaryl compounds and methods of use thereof
|
WO2011150201A2
(en)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Azolyl amide compounds and methods of use thereof
|
WO2011150198A1
(en)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Azolyl urea compounds and methods of use thereof
|
EP2576520A1
(en)
|
2010-05-28 |
2013-04-10 |
GE Healthcare UK Limited |
Radiolabeled compounds and methods thereof
|
EP2585063A1
(en)
|
2010-06-01 |
2013-05-01 |
Biotheryx Inc. |
Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridone
|
MX2012013879A
(es)
|
2010-06-01 |
2013-04-03 |
Biotheryx Inc |
Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas.
|
JP5855095B2
(ja)
|
2010-06-07 |
2016-02-09 |
ノボメディックス,エルエルシーNovomedix,Llc |
フラニル化合物およびその使用
|
US20140200270A1
(en)
|
2013-01-11 |
2014-07-17 |
Summa Health System |
Vitamins c and k for treating polycystic diseases
|
AU2011279808B2
(en)
|
2010-07-19 |
2015-07-02 |
Mayo Foundation For Medical Education And Research (Mfmer) |
Vitamin C and chromium-free vitamin K, and compositions thereof for treating an NFKB-mediated condition or disease
|
US8957098B2
(en)
|
2010-08-24 |
2015-02-17 |
Algiax Pharmaceuticals Gmbh |
Use of leflunomide and malononitrilamides
|
MX2013002384A
(es)
|
2010-09-01 |
2013-07-05 |
Ambit Biosciences Corp |
Compuestos quinazolina y metodos para utilizarlos.
|
EP2611795B1
(en)
|
2010-09-01 |
2016-05-04 |
Ambit Biosciences Corporation |
An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
|
US20130303533A1
(en)
|
2010-09-01 |
2013-11-14 |
Ambit Biosciences Corporation |
Azolopyridine and azolopyrimidine compounds and methods of use thereof
|
WO2012030944A2
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Quinoline and isoquinoline compounds and methods of use thereof
|
US20120053176A1
(en)
|
2010-09-01 |
2012-03-01 |
Ambit Biosciences Corp. |
Adenosine a3 receptor modulating compounds and methods of use thereof
|
WO2012030914A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Boisciences Corporation |
4-azolylaminoquinazoline derivatives and methods of use thereof
|
US20130317045A1
(en)
|
2010-09-01 |
2013-11-28 |
Ambit Biosciences Corporation |
Thienopyridine and thienopyrimidine compounds and methods of use thereof
|
WO2012030912A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
7-cyclylquinazoline derivatives and methods of use thereof
|
WO2012030910A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
2-cycloquinazoline derivatives and methods of use thereof
|
CA2809983A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Hydrobromide salts of a pyrazolylaminoquinazoline
|
CN103269701A
(zh)
|
2010-09-13 |
2013-08-28 |
辛塔医药品有限公司 |
用于治疗野生型egfr和/或kras患者的非小细胞肺癌的hsp90抑制剂
|
WO2012044641A1
(en)
|
2010-09-29 |
2012-04-05 |
Pathway Therapeutics Inc. |
1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
EP2627635A1
(en)
|
2010-10-11 |
2013-08-21 |
Axikin Pharmaceuticals, Inc. |
Salts of arylsulfonamide ccr3 antagonists
|
CN103391784A
(zh)
|
2010-10-15 |
2013-11-13 |
纽约市哥伦比亚大学理事会 |
肥胖症-相关的基因和它们的蛋白和其用途
|
NO2629776T3
(it)
|
2010-10-18 |
2018-01-13 |
|
|
CA2815024A1
(en)
|
2010-10-19 |
2012-04-26 |
Elcelyx Therapeutics, Inc. |
Chemosensory receptor ligand-based therapies
|
DK2632451T3
(en)
|
2010-10-29 |
2017-12-18 |
Algiax Pharmaceuticals Gmbh |
USE OF MALONNITRILAMIDS IN NEUROPATHIC PAIN
|
EP2638032A1
(en)
|
2010-11-09 |
2013-09-18 |
Synta Pharmaceuticals Corp. |
Tetrazolyl - tetrahydropyridine compounds for inflammation and immune - related uses
|
WO2012064973A2
(en)
|
2010-11-10 |
2012-05-18 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
GB201020032D0
(en)
|
2010-11-25 |
2011-01-12 |
Sigmoid Pharma Ltd |
Composition
|
US20140031325A1
(en)
|
2010-12-06 |
2014-01-30 |
Celgene Corporation |
Combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
|
JP2014500275A
(ja)
|
2010-12-06 |
2014-01-09 |
フォリカ,インコーポレイテッド |
禿頭症を治療するため、および毛髪の成長を促進するための方法
|
WO2012078757A2
(en)
|
2010-12-08 |
2012-06-14 |
Synta Pharmaceuticals Corp. |
Combination breast cancer therapy with hsp90 inhibitory compounds
|
WO2012080050A1
(en)
|
2010-12-14 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Solid forms of a phenoxybenzenesulfonyl compound
|
WO2012083017A2
(en)
|
2010-12-16 |
2012-06-21 |
Celgene Corporation |
Controlled release oral dosage forms of poorly soluble drugs and uses thereof
|
US9532977B2
(en)
|
2010-12-16 |
2017-01-03 |
Celgene Corporation |
Controlled release oral dosage forms of poorly soluble drugs and uses thereof
|
EP2654751B1
(en)
|
2010-12-22 |
2016-11-23 |
Purdue Pharma L.P. |
Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof
|
WO2014011926A1
(en)
|
2012-07-11 |
2014-01-16 |
Elcelyx Therapeutics, Inc. |
Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
|
CA2823397C
(en)
|
2011-01-07 |
2020-03-10 |
Elcelyx Therapeutics, Inc. |
Chemosensory receptor ligand-based therapies
|
CN103391770A
(zh)
|
2011-01-10 |
2013-11-13 |
细胞基因公司 |
环丙烷羧酸{2-[(1s)-1-(3-乙氧基-4-甲氧基-苯基)-2-甲烷磺酰基-乙基]-3-氧代-2,3-二氢-1h-异吲哚-4-基}-酰胺的口服剂型
|
CN103402980B
(zh)
|
2011-01-10 |
2016-06-29 |
细胞基因公司 |
作为pde4和/或细胞因子抑制剂的苯乙基砜异吲哚啉衍生物
|
AR084824A1
(es)
|
2011-01-10 |
2013-06-26 |
Intellikine Inc |
Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas
|
EP3210984B1
(en)
|
2011-01-11 |
2019-06-19 |
Sunovion Pharmaceuticals Inc. |
Heteroaryl compounds and methods of use thereof
|
US20130331357A1
(en)
|
2011-01-11 |
2013-12-12 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors
|
US9045417B2
(en)
|
2011-01-14 |
2015-06-02 |
Celgene Corporation |
Isotopologues of isoindole derivatives
|
RS54447B1
(en)
|
2011-01-20 |
2016-06-30 |
Bionevia Pharmaceuticals Inc. |
MODIFIED LABELING COMPOSITIONS OF EPALRESTAT OR ITS DERIVATIVES AND PROCEDURES FOR THEIR USE
|
US9428565B2
(en)
|
2011-01-31 |
2016-08-30 |
The General Hospital Corporation |
Treatment and bioluminescent visualization using multimodal TRAIL molecules
|
EP2670396A1
(en)
|
2011-01-31 |
2013-12-11 |
Celgene Corporation |
Pharmaceutical compositions of cytidine analogs and methods of use thereof
|
US9353100B2
(en)
|
2011-02-10 |
2016-05-31 |
Idenix Pharmaceuticals Llc |
Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
|
EP2678013A1
(en)
|
2011-02-23 |
2014-01-01 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitory compounds with radiotherapy
|
WO2012141796A2
(en)
|
2011-02-24 |
2012-10-18 |
Synta Pharmaceuticals Corp. |
Prostate cancer therapy with hsp90 inhibitory compounds
|
US9795792B2
(en)
|
2011-02-25 |
2017-10-24 |
Medtronic, Inc. |
Emergency mode switching for non-pacing modes
|
US20140045908A1
(en)
|
2011-02-25 |
2014-02-13 |
Synta Pharmaceuticals Corp. |
Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers
|
WO2012121988A2
(en)
|
2011-03-07 |
2012-09-13 |
Celgene Corporation |
Methods for treating diseases using isoindoline compounds
|
AR085651A1
(es)
|
2011-03-11 |
2013-10-16 |
Celgene Corp |
Metodos para tratar cancer usando 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona
|
DK2683708T3
(da)
|
2011-03-11 |
2018-01-29 |
Celgene Corp |
Faste former af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion og farmaceutiske sammensætninger og anvendelser deraf
|
WO2012123353A1
(en)
|
2011-03-17 |
2012-09-20 |
Algiax Pharmaceuticals Gmbh |
Novel use of benzofuranylsulfonates
|
WO2012123406A1
(en)
|
2011-03-17 |
2012-09-20 |
Algiax Pharmaceuticals Gmbh |
Novel use of imidazotriazinones
|
WO2012129237A2
(en)
|
2011-03-20 |
2012-09-27 |
Trustees Of Boston University |
Therapeutic agent for emphysema and copd
|
EP2691388A1
(en)
|
2011-03-28 |
2014-02-05 |
MEI Pharma, Inc. |
(fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
EP2691384B1
(en)
|
2011-03-28 |
2016-10-26 |
MEI Pharma, Inc. |
(alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
|
CA2831590A1
(en)
|
2011-03-28 |
2012-10-04 |
Mei Pharma, Inc. |
(alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
AU2012236655B2
(en)
|
2011-03-28 |
2016-09-22 |
Deuterx, Llc, |
2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
|
WO2012154321A1
(en)
|
2011-03-31 |
2012-11-15 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
WO2012158271A1
(en)
|
2011-04-06 |
2012-11-22 |
Anadys Pharmaceuticals, Inc. |
Bridged polycyclic compounds as antiviral agents
|
ES2804223T3
(es)
|
2011-04-21 |
2021-02-04 |
Curemark Llc |
Compuestos para el tratamiento de Trastornos Neuropsiquiátricos
|
EP2699317B1
(en)
|
2011-04-21 |
2016-08-10 |
Mapi Pharma Limited |
Random pentapolymer for treatment of autoimmune diseases
|
WO2012149251A1
(en)
|
2011-04-28 |
2012-11-01 |
Celgene Corporation |
Methods and compositions using pde4 inhibitors for the treatment and management of autoimmune and inflammatory diseases
|
JP6016892B2
(ja)
|
2011-04-29 |
2016-10-26 |
セルジーン コーポレイション |
セレブロンを予測因子として使用する癌及び炎症性疾患の治療方法
|
US9604978B2
(en)
|
2011-05-03 |
2017-03-28 |
Synta Pharmaceuticals Corp. |
Compounds for inflammation and immune-related uses
|
EP2704726B1
(en)
|
2011-05-04 |
2018-10-31 |
Trustees of Boston University |
Proton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria
|
EP2714038A1
(en)
|
2011-05-24 |
2014-04-09 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitory compounds with mtor/pi3k inhibitors
|
AU2012262489A1
(en)
|
2011-05-27 |
2013-04-04 |
Icahn School Of Medicine At Mount Sinai |
Substituted 2-benzylidene-2H-benzo[b][1,4]thiazin-3(4H)-ones, derivatives thereof, and therapeutic uses thereof
|
CN103827100B
(zh)
|
2011-06-07 |
2015-08-12 |
安那迪斯药品股份有限公司 |
用于降低血清尿酸的[1,2,4]噻二嗪1,1-二氧化物化合物
|
RU2011122942A
(ru)
|
2011-06-08 |
2012-12-20 |
Общество С Ограниченной Ответственностью "Асинэкс Медхим" |
Новые ингибиторы киназ
|
PE20141531A1
(es)
|
2011-06-22 |
2014-10-23 |
Purdue Pharma Lp |
Antagonistas de trpv1 que incluyen sustituyentes dihidroxi y sus usos
|
US20140221427A1
(en)
|
2011-06-22 |
2014-08-07 |
Celgene Corporation |
Isotopologues of pomalidomide
|
KR20140042868A
(ko)
|
2011-06-23 |
2014-04-07 |
맵 파마슈티컬스, 인코포레이티드 |
신규한 플루오로에르골린 유사체
|
WO2013003697A1
(en)
|
2011-06-30 |
2013-01-03 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
CA2840986A1
(en)
|
2011-07-07 |
2013-01-10 |
Synta Pharmaceuticals Corp. |
Treating cancer with hsp90 inhibitory compounds
|
AU2012284088B2
(en)
|
2011-07-19 |
2015-10-08 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
CN103946226A
(zh)
|
2011-07-19 |
2014-07-23 |
无限药品股份有限公司 |
杂环化合物及其应用
|
GB201112987D0
(en)
|
2011-07-28 |
2011-09-14 |
Ge Healthcare Ltd |
Novel compound
|
AU2012293417A1
(en)
|
2011-08-10 |
2013-05-02 |
Purdue Pharma L.P. |
TRPV1 antagonists including dihydroxy substituent and uses thereof
|
WO2013022872A1
(en)
|
2011-08-10 |
2013-02-14 |
Celgene Corporation |
Gene methylation biomarkers and methods of use thereof
|
CN103930126A
(zh)
|
2011-08-12 |
2014-07-16 |
Bsrc亚历山大.弗莱明 |
Tnf超家族三聚化的抑制剂
|
CA2844809A1
(en)
|
2011-08-19 |
2013-02-28 |
Synta Pharmaceuticals Corp. |
Combination cancer therapy of hsp90 inhibitor with antimetabolite
|
EP2747762B1
(en)
|
2011-08-23 |
2015-07-01 |
Cornerstone Therapeutics Inc. |
Use of zileuton for the treatment of nasal polyps in cystic fibrosis patients
|
WO2013032591A1
(en)
|
2011-08-29 |
2013-03-07 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
WO2013039920A1
(en)
|
2011-09-12 |
2013-03-21 |
Idenix Pharmaceuticals, Inc. |
Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
|
AU2012308900A1
(en)
|
2011-09-12 |
2013-05-09 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
US20130071394A1
(en)
|
2011-09-16 |
2013-03-21 |
John K. Troyer |
Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
|
US20130085115A1
(en)
|
2011-09-23 |
2013-04-04 |
Celgene Corporation |
Combination therapy for lymphoma
|
JP2014526564A
(ja)
|
2011-09-26 |
2014-10-06 |
セルジーン コーポレイション |
化学療法抵抗性癌の併用療法
|
WO2013049332A1
(en)
|
2011-09-29 |
2013-04-04 |
Infinity Pharmaceuticals, Inc. |
Inhibitors of monoacylglycerol lipase and methods of their use
|
WO2013052776A1
(en)
|
2011-10-07 |
2013-04-11 |
Cedars-Sinai Medical Center |
Compositions and methods for tumor imaging and targeting by a class of organic heptamethine cyanine dyes that possess dual nuclear and near-infrared properties
|
EP2766041B1
(en)
|
2011-10-12 |
2018-12-05 |
Children's Medical Center Corporation |
Combinatorial compositions and methods of treating hemoglobinopathies
|
EP2768838A1
(en)
|
2011-10-14 |
2014-08-27 |
IDENIX Pharmaceuticals, Inc. |
Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
|
PT2766359T
(pt)
|
2011-10-14 |
2016-07-14 |
Ambit Biosciences Corp |
Compostos heterocíclicos e utilização dos mesmos como moduladores de recetores tirosina-cinase de tipo iii
|
CA2853949A1
(en)
|
2011-11-01 |
2013-05-10 |
Celgene Corporation |
Methods for treating cancers using oral formulations of cytidine analogs
|
CA2853806C
(en)
|
2011-11-02 |
2020-07-14 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitors with platinum-containing agents
|
CA2853799A1
(en)
|
2011-11-02 |
2013-05-10 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
|
US10357496B2
(en)
*
|
2011-11-05 |
2019-07-23 |
South Alabama Medical Science Foundation |
Methods, formulations, and kits for rapidly repleting folate levels in women
|
US9243037B2
(en)
|
2011-11-10 |
2016-01-26 |
Trustees Of Boston College |
Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity
|
CA2854188A1
(en)
|
2011-11-14 |
2013-05-23 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitors with braf inhibitors
|
AU2012324015A1
(en)
|
2011-12-01 |
2013-06-20 |
Purdue Pharma L.P. |
Azetidine-substituted quinoxaline-type piperidine compounds and uses thererof
|
US20130143867A1
(en)
|
2011-12-02 |
2013-06-06 |
Sychroneuron Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
WO2013085902A1
(en)
|
2011-12-05 |
2013-06-13 |
The University Of Texas M.D. |
Combination therapy methods for treating an inflammatory breast cancer
|
AU2012324012A1
(en)
|
2011-12-08 |
2013-06-27 |
Purdue Pharma L.P. |
Quaternized buprenorphine analogs
|
SG10201509139QA
(en)
|
2011-12-19 |
2015-12-30 |
Map Pharmaceuticals Inc |
Novel iso-ergoline derivatives
|
SG11201403433PA
(en)
|
2011-12-21 |
2014-07-30 |
Map Pharmaceuticals Inc |
Novel neuromodulatory compounds
|
IL298330A
(en)
|
2011-12-30 |
2023-01-01 |
Halozyme Inc |
Ph20 polypeptide variants, formulations and uses thereof
|
SG10201605361RA
(en)
|
2012-01-05 |
2016-08-30 |
Boston Medical Ct Corp |
Slit-Robo Signaling for Diagnosis and Treatment of Kidney Disease
|
KR20190120430A
(ko)
|
2012-01-06 |
2019-10-23 |
엘셀릭스 테라퓨틱스 인코포레이티드 |
바이구아나이드 조성물 및 대사 장애를 치료하는 방법
|
AU2013207329B2
(en)
|
2012-01-06 |
2017-10-26 |
Anji Pharmaceuticals Inc. |
Compositions and methods for treating metabolic disorders
|
AU2013216935C1
(en)
|
2012-02-08 |
2017-12-14 |
John Emmerson Campbell |
Heteroaryl compounds and methods of use thereof
|
WO2013126394A1
(en)
|
2012-02-21 |
2013-08-29 |
Celgene Corporation |
Solid forms of 3-(4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione
|
US20150018362A1
(en)
|
2012-02-27 |
2015-01-15 |
Biovista, Inc. |
Compositions and methods for treating mitochondrial diseases
|
US9611253B2
(en)
|
2012-02-29 |
2017-04-04 |
Ambit Biosciences Corporation |
Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
|
WO2013133708A1
(en)
|
2012-03-07 |
2013-09-12 |
Stichting Vu-Vumc |
Compositions and methods for diagnosing and treating intellectual disability syndrome, autism and autism related disorders
|
AU2013205306B2
(en)
|
2012-03-16 |
2015-09-17 |
Axikin Pharmaceuticals, Inc. |
3,5-diaminopyrazole kinase inhibitors
|
JP6124986B2
(ja)
|
2012-03-19 |
2017-05-10 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. |
拡張期心不全を処置するための増殖分化因子(gdf)
|
US10039777B2
(en)
|
2012-03-20 |
2018-08-07 |
Neuro-Lm Sas |
Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
|
US20140350087A9
(en)
|
2012-03-22 |
2014-11-27 |
Halozyme, Inc. |
Oncovector Nucleic Acid Molecules and Methods of Use
|
US9169207B2
(en)
|
2012-03-27 |
2015-10-27 |
Incuron, Llc |
Curaxins for use in treating carcinogen-induced cancer
|
EP2831061A1
(en)
|
2012-03-28 |
2015-02-04 |
Synta Pharmaceuticals Corp. |
Triazole derivatives as hsp90 inhibitors
|
US20150119395A1
(en)
|
2012-04-04 |
2015-04-30 |
Synta Pharmaceuticals Corp. |
Novel triazole compounds that modulate hsp90 activity
|
EA031986B1
(ru)
|
2012-04-04 |
2019-03-29 |
Галозим, Инк. |
Способ и комбинация для лечения солидной раковой опухоли и набор, содержащий комбинацию
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2013156232A1
(en)
|
2012-04-16 |
2013-10-24 |
Algiax Pharmaceuticals Gmbh |
Use of benzofuranylsulfonates in neuropathic pain
|
WO2013156231A1
(en)
|
2012-04-16 |
2013-10-24 |
Algiax Pharmaceuticals Gmbh |
Use of imidazotriazinones in neuropathic pain
|
SG11201406025UA
(en)
|
2012-04-17 |
2014-11-27 |
Purdue Pharma Lp |
Systems and methods for treating an opioid-induced adverse pharmacodynamic response
|
WO2013158928A2
(en)
|
2012-04-18 |
2013-10-24 |
Elcelyx Therapeutics, Inc. |
Chemosensory receptor ligand-based therapies
|
AU2013255050B2
(en)
|
2012-05-01 |
2016-07-28 |
Translatum Medicus Inc. |
Methods for treating and diagnosing blinding eye diseases
|
WO2013170159A1
(en)
|
2012-05-10 |
2013-11-14 |
Synta Pharmaceuticals Corp. |
Treating cancer with hsp90 inhibitory compounds
|
AR091027A1
(es)
|
2012-05-11 |
2014-12-30 |
Purdue Pharma Lp |
Analogos de benzomorfano y el usos de estos
|
EP2852605B1
(en)
|
2012-05-22 |
2018-01-31 |
Idenix Pharmaceuticals LLC |
3',5'-cyclic phosphate prodrugs for hcv infection
|
WO2013177188A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
3',5'-cyclic phosphoramidate prodrugs for hcv infection
|
AP3913A
(en)
|
2012-05-22 |
2016-11-26 |
Idenix Pharamaceuticals Inc |
D-amino acid compounds for liver disease
|
US10350278B2
(en)
|
2012-05-30 |
2019-07-16 |
Curemark, Llc |
Methods of treating Celiac disease
|
WO2013187965A1
(en)
|
2012-06-14 |
2013-12-19 |
Mayo Foundation For Medical Education And Research |
Pyrazole derivatives as inhibitors of stat3
|
BR112014031421A2
(pt)
|
2012-06-15 |
2017-06-27 |
Brigham & Womens Hospital Inc |
composições para tratamento de câncer e métodos para produção das mesmas
|
US9012640B2
(en)
|
2012-06-22 |
2015-04-21 |
Map Pharmaceuticals, Inc. |
Cabergoline derivatives
|
WO2014004990A2
(en)
|
2012-06-29 |
2014-01-03 |
Celgene Corporation |
Methods for determining drug efficacy using cereblon-associated proteins
|
GB201212010D0
(en)
|
2012-07-05 |
2012-08-22 |
Sigmoid Pharma Ltd |
Formulations
|
US9034870B2
(en)
|
2012-07-13 |
2015-05-19 |
Purdue Research Foundation |
Azaindenoisoquinoline topoisomerase I inhibitors
|
US9085561B2
(en)
|
2012-07-30 |
2015-07-21 |
Purdue Pharma L.P. |
Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators
|
US10513540B2
(en)
|
2012-07-31 |
2019-12-24 |
The Brigham And Women's Hospital, Inc. |
Modulation of the immune response
|
TW201408657A
(zh)
|
2012-08-09 |
2014-03-01 |
Celgene Corp |
(s)-3-(4-((4-(嗎啉基甲基)苄基)氧基)-1-氧異吲哚啉-2-基)哌啶-2,6-二酮之鹽及固態形式、包含其之組合物及其使用方法
|
SI2882441T1
(sl)
|
2012-08-09 |
2020-08-31 |
Celgene Corporation |
Zdravljenje bolezni v zvezi z imunskim sistemom in vnetnih bolezni
|
EP2882442B1
(en)
|
2012-08-09 |
2021-06-09 |
Celgene Corporation |
Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
|
US9587281B2
(en)
|
2012-08-14 |
2017-03-07 |
Celgene Corporation |
Cereblon isoforms and their use as biomarkers for therapeutic treatment
|
US10624859B2
(en)
|
2012-08-20 |
2020-04-21 |
Rhodes Technologies |
Systems and methods for increasing stability of dronabinol compositions
|
US9315514B2
(en)
|
2012-08-27 |
2016-04-19 |
Rhodes Technologies |
1,3-dioxanomorphides and 1,3-dioxanocodides
|
US9605074B2
(en)
|
2012-08-30 |
2017-03-28 |
The General Hospital Corporation |
Multifunctional nanobodies for treating cancer
|
US9750705B2
(en)
|
2012-08-31 |
2017-09-05 |
The Regents Of The University Of California |
Agents useful for treating obesity, diabetes and related disorders
|
EP2892884A1
(en)
|
2012-09-07 |
2015-07-15 |
Axikin Pharmaceuticals, Inc. |
Isotopically enriched arylsulfonamide ccr3 antagonists
|
BR112015005243A2
(pt)
|
2012-09-10 |
2017-07-04 |
Celgene Corp |
métodos para o tratamento de câncer de mama localmente avançado
|
WO2014055647A1
(en)
|
2012-10-03 |
2014-04-10 |
Mei Pharma, Inc. |
(sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
|
PE20151318A1
(es)
|
2012-10-08 |
2015-10-03 |
Idenix Pharmaceuticals Inc |
Analogos de 2'-cloro nucleosido para infeccion por vhc
|
EP2906241B1
(en)
|
2012-10-12 |
2020-01-08 |
The Brigham and Women's Hospital, Inc. |
Enhancement of the immune response
|
US9278124B2
(en)
|
2012-10-16 |
2016-03-08 |
Halozyme, Inc. |
Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
|
WO2014063019A1
(en)
|
2012-10-19 |
2014-04-24 |
Idenix Pharmaceuticals, Inc. |
Dinucleotide compounds for hcv infection
|
US10723754B2
(en)
|
2012-10-22 |
2020-07-28 |
Idenix Pharmaceuticals Llc |
2′,4′-bridged nucleosides for HCV infection
|
NZ744567A
(en)
|
2012-11-01 |
2020-03-27 |
Infinity Pharmaceuticals Inc |
Treatment of cancers using pi3 kinase isoform modulators
|
CA2890177A1
(en)
|
2012-11-08 |
2014-05-15 |
Summa Health System |
Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
|
US20150290171A1
(en)
|
2012-11-09 |
2015-10-15 |
Celgene Corporation |
Methods for the treatment of bone loss
|
JP6400592B2
(ja)
|
2012-11-09 |
2018-10-03 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
ベンゾモルファン類似体およびその使用
|
US20140140951A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-Alanine Ester of Rp-Nucleoside Analog
|
WO2014078436A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-alanine ester of sp-nucleoside analog
|
CA2889906A1
(en)
|
2012-11-29 |
2014-06-05 |
Sunovion Pharmaceuticals Inc. |
Triazolo-pyrazine derivatives useful in the treatment of disorders of the central nervous system
|
KR102180342B1
(ko)
|
2012-11-30 |
2020-11-18 |
노보메딕스 엘엘씨 |
치환된 바이아릴 설폰아미드 및 이의 용도
|
EP2931729B1
(en)
|
2012-12-07 |
2019-02-06 |
Purdue Pharma LP |
Buprenorphine analogs as opiod receptor modulators
|
JP6163210B2
(ja)
|
2012-12-14 |
2017-07-12 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
窒素含有モルフィナン誘導体およびその使用
|
US8980906B2
(en)
|
2012-12-14 |
2015-03-17 |
Purdue Pharma L.P. |
Pyridonemorphinan analogs and biological activity on opioid receptors
|
TW201434837A
(zh)
|
2012-12-14 |
2014-09-16 |
Purdue Pharma Lp |
螺環嗎啡喃及其用途
|
EP2935304A1
(en)
|
2012-12-19 |
2015-10-28 |
IDENIX Pharmaceuticals, Inc. |
4'-fluoro nucleosides for the treatment of hcv
|
BR112015014964A2
(pt)
|
2012-12-21 |
2017-07-11 |
Map Pharmaceuticals Inc |
novos derivados de metisergida
|
US9951038B2
(en)
|
2012-12-27 |
2018-04-24 |
Purdue Pharma L.P. |
Quinazolin-4(3H)-one-type piperidine compounds and uses thereof
|
US9963458B2
(en)
|
2012-12-27 |
2018-05-08 |
Purdue Pharma L.P. |
Indole and indoline-type piperidine compounds and uses thereof
|
WO2014102592A2
(en)
|
2012-12-27 |
2014-07-03 |
Purdue Pharma L.P. |
Oxime/substituted quinoxaline-type piperidine compounds and uses thereof
|
US9090618B2
(en)
|
2012-12-27 |
2015-07-28 |
Purdue Pharma L.P. |
Substituted benzimidazole-type piperidine compounds and uses thereof
|
US10118927B2
(en)
|
2012-12-27 |
2018-11-06 |
Purdue Pharma L.P. |
Substituted piperidin-4-amino-type compounds and uses thereof
|
JP6159416B2
(ja)
|
2012-12-28 |
2017-07-05 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
7,8−環式モルフィナン類似体
|
CA2896202A1
(en)
|
2012-12-28 |
2014-07-03 |
Purdue Pharma L.P. |
Substituted morphinans and the use thereof
|
CA2896871A1
(en)
|
2012-12-31 |
2014-07-03 |
Kerry L. Spear |
Heterocyclic compounds and methods of use thereof
|
MX2015008625A
(es)
|
2013-01-05 |
2015-09-23 |
Elcelyx Therapeutics Inc |
Composicion de liberacion demorada que comprende biguanida.
|
US20150196625A9
(en)
|
2013-01-07 |
2015-07-16 |
Rudolph D. Paladini |
Metal Sensitive Mutants of Matrix Metalloproteases and uses thereof
|
EP2943593B1
(en)
|
2013-01-08 |
2019-04-24 |
Enzo Biochem, Inc. |
Diagnosis and treatment of herpesvirus saimiri associated diseases
|
US9617607B2
(en)
|
2013-01-08 |
2017-04-11 |
Enzo Biochem, Inc. |
Diagnosis and treatment of viral diseases
|
CA2935495C
(en)
|
2013-01-14 |
2021-04-20 |
Deuterx, Llc |
3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
|
US9695145B2
(en)
|
2013-01-22 |
2017-07-04 |
Celgene Corporation |
Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
|
EP2950799B1
(en)
|
2013-01-30 |
2019-12-04 |
Pharmorx Therapeutics, Inc. |
Treatments for depression and other diseases with a low dose agent
|
WO2014118618A1
(en)
|
2013-01-31 |
2014-08-07 |
Purdue Pharma L.P. |
Benzomorphan analogs and the use thereof
|
WO2014130922A1
(en)
|
2013-02-25 |
2014-08-28 |
Trustees Of Boston University |
Compositions and methods for treating fungal infections
|
WO2014137926A1
(en)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
3'-deoxy nucleosides for the treatment of hcv
|
US9339541B2
(en)
|
2013-03-04 |
2016-05-17 |
Merck Sharp & Dohme Corp. |
Thiophosphate nucleosides for the treatment of HCV
|
KR20150126618A
(ko)
|
2013-03-14 |
2015-11-12 |
셀진 코포레이션 |
아프레밀라스트를 사용하는 건선성 관절염의 치료
|
NZ629037A
(en)
|
2013-03-15 |
2017-04-28 |
Infinity Pharmaceuticals Inc |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
US8969358B2
(en)
|
2013-03-15 |
2015-03-03 |
Purdue Pharma L.P. |
Buprenorphine analogs
|
RS57796B1
(sr)
|
2013-03-15 |
2018-12-31 |
Univ California |
Diestri acikličnog nukleozid fosfonata
|
US9187515B2
(en)
|
2013-04-01 |
2015-11-17 |
Idenix Pharmaceuticals Llc |
2′,4′-fluoro nucleosides for the treatment of HCV
|
JP6469077B2
(ja)
|
2013-04-02 |
2019-02-13 |
セルジーン コーポレイション |
4−アミノ−2−(2,6−ジオキソ−ピペリジン3−イル)−イソインドリン−1,3−ジオンを使用する中枢神経の癌の治療及び管理のための方法及び組成物
|
US10092627B2
(en)
|
2013-04-08 |
2018-10-09 |
President And Fellows Of Harvard College |
Methods and compositions for rejuvenating skeletal muscle stem cells
|
BR112015029969A2
(pt)
|
2013-05-30 |
2017-07-25 |
Infinity Pharmaceuticals Inc |
tratamento de câncer usando moduladores de isoformas quinase pi3
|
EP3004130B1
(en)
|
2013-06-05 |
2019-08-07 |
Idenix Pharmaceuticals LLC. |
1',4'-thio nucleosides for the treatment of hcv
|
EP3003297A4
(en)
|
2013-06-05 |
2017-04-19 |
Synchroneuron Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
EP3004396B1
(en)
|
2013-06-06 |
2019-10-16 |
The General Hospital Corporation |
Compositions for the treatment of cancer
|
US20160220640A1
(en)
|
2013-06-11 |
2016-08-04 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions for increasing neurogenesis and angiogenesis
|
JP6800748B2
(ja)
|
2013-06-14 |
2020-12-16 |
アカマラ セラピューティクス、インコーポレイテッド |
脂質ベース白金化合物およびナノ粒子
|
EP2815749A1
(en)
|
2013-06-20 |
2014-12-24 |
IP Gesellschaft für Management mbH |
Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
|
ES2703623T3
(es)
|
2013-06-28 |
2019-03-11 |
Purdue Pharma Lp |
Antagonistas opioides para uso en el tratamiento de una arritmia inducida por analgésicos opioides
|
TW201534726A
(zh)
|
2013-07-03 |
2015-09-16 |
Halozyme Inc |
熱穩定ph20玻尿酸酶變異體及其用途
|
WO2015017713A1
(en)
|
2013-08-01 |
2015-02-05 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
|
EP3036226B1
(en)
|
2013-08-22 |
2020-01-08 |
The General Hospital Corporation |
Inhibitors of human 12/15-lipoxygenase
|
CA2922361C
(en)
|
2013-08-29 |
2022-07-12 |
Trustees Of Boston University |
Intermediate metabolism products to potentiate aminoglycoside antibiotics in bacterial infections
|
WO2015031613A1
(en)
|
2013-08-30 |
2015-03-05 |
Ambit Biosciences Corporation |
Biaryl acetamide compounds and methods of use thereof
|
NZ631142A
(en)
|
2013-09-18 |
2016-03-31 |
Axikin Pharmaceuticals Inc |
Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
|
EP3046924A1
(en)
|
2013-09-20 |
2016-07-27 |
IDENIX Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
EP3049082B1
(en)
|
2013-09-24 |
2019-05-22 |
Purdue Pharma L.P. |
Treatment of burn pain by trpv1 modulators
|
WO2015051336A1
(en)
|
2013-10-03 |
2015-04-09 |
David Wise |
Compositions and methods for treating pelvic pain and other conditions
|
WO2015051241A1
(en)
|
2013-10-04 |
2015-04-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
JP6466924B2
(ja)
|
2013-10-04 |
2019-02-06 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
複素環式化合物及びその使用
|
EP3967770B1
(en)
|
2013-10-21 |
2023-12-06 |
The General Hospital Corporation |
Methods relating to circulating tumor cell clusters and the treatment of cancer
|
US20160244452A1
(en)
|
2013-10-21 |
2016-08-25 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2015061683A1
(en)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
|
US9750757B2
(en)
|
2013-10-29 |
2017-09-05 |
Thomas Jefferson University |
Methods of prevention or treatment for pathologic thrombosis or inflammation
|
EP3063165A1
(en)
|
2013-11-01 |
2016-09-07 |
Idenix Pharmaceuticals LLC |
D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
|
GB201319792D0
(en)
|
2013-11-08 |
2013-12-25 |
Sigmoid Pharma Ltd |
Formulations
|
NZ719268A
(en)
|
2013-11-11 |
2021-07-30 |
Naturex Dbs Llc |
Compositions and methods useful in treatment of lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction
|
JP6620094B2
(ja)
|
2013-11-26 |
2019-12-11 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. |
免疫応答を調節するための組成物および方法
|
US20170198005A1
(en)
|
2013-11-27 |
2017-07-13 |
Idenix Pharmaceuticals Llc |
2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
|
US10030044B2
(en)
|
2013-11-27 |
2018-07-24 |
Idenix Pharmaceuticals Llc |
Nucleotides for the treatment of liver cancer
|
AU2014362307A1
(en)
|
2013-12-11 |
2016-06-30 |
The General Hospital Corporation |
Use of mullerian inhibiting substance (MIS) proteins for contraception and ovarian reserve preservation
|
EP3083654A1
(en)
|
2013-12-18 |
2016-10-26 |
Idenix Pharmaceuticals LLC |
4'-or nucleosides for the treatment of hcv
|
US9682123B2
(en)
|
2013-12-20 |
2017-06-20 |
The Trustees Of Columbia University In The City Of New York |
Methods of treating metabolic disease
|
EP3082840B1
(en)
|
2013-12-20 |
2021-03-24 |
The General Hospital Corporation |
Methods and assays relating to circulating tumor cells
|
EP3087078B1
(en)
|
2013-12-26 |
2019-05-15 |
Purdue Pharma LP |
7-beta-alkyl analogs of orvinols
|
US9994571B2
(en)
|
2013-12-26 |
2018-06-12 |
Purdue Pharma L.P. |
10-substituted morphinan hydantoins
|
EP3087079B1
(en)
|
2013-12-26 |
2019-04-03 |
Purdue Pharma LP |
Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
|
US9340542B2
(en)
|
2013-12-26 |
2016-05-17 |
Purdue Pharma L.P. |
Propellane-based compounds and the use thereof
|
WO2015099863A1
(en)
|
2013-12-27 |
2015-07-02 |
Purdue Pharma L.P. |
6-substituted and 7-substituted morphinan analogs and the use thereof
|
US9902726B2
(en)
|
2013-12-30 |
2018-02-27 |
Purdue Pharma L.P. |
Pyridone-sulfone morphinan analogs as opioid receptor ligands
|
US10188639B2
(en)
|
2014-01-15 |
2019-01-29 |
Deuterx, Llc |
Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
|
ES2733552T3
(es)
|
2014-01-24 |
2019-11-29 |
Celgene Corp |
Procedimientos para el tratamiento de la obesidad mediante apremilast
|
US20170066779A1
(en)
|
2014-03-05 |
2017-03-09 |
Idenix Pharmaceuticals Llc |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
EP3116507B1
(en)
|
2014-03-10 |
2021-05-26 |
Kadmon Corporation, LLC |
Compounds for oral treatment of brain tumors
|
WO2015140081A1
(en)
|
2014-03-18 |
2015-09-24 |
Algiax Pharmaceuticals Gmbh |
2-cyano-3-cyclopropyl-3-hydroxy-n-aryl-thioacrylamide derivatives
|
US9775844B2
(en)
|
2014-03-19 |
2017-10-03 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2015143161A1
(en)
|
2014-03-20 |
2015-09-24 |
Capella Therapeutics, Inc. |
Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
|
US11369588B2
(en)
|
2014-03-20 |
2022-06-28 |
The Trustees Of Princeton University |
NADPH production by the 10-formyl-THF pathway, and its use in the diagnosis and treatment of disease
|
RU2741914C2
(ru)
|
2014-03-20 |
2021-01-29 |
Капелла Терапьютикс, Инк. |
Производные бензимидазола как ингибиторы тирозинкиназ erbb для лечения рака
|
EP3119913B1
(en)
|
2014-03-21 |
2021-01-06 |
The Brigham and Women's Hospital, Inc. |
Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
|
KR20160132496A
(ko)
|
2014-04-03 |
2016-11-18 |
인빅터스 온콜로지 피비티. 엘티디. |
초분자 조합 치료제
|
US20170216328A1
(en)
|
2014-04-04 |
2017-08-03 |
Ritter Pharmaceuticals, Inc. |
Methods and compositions for microbiome alteration
|
WO2015157559A2
(en)
|
2014-04-09 |
2015-10-15 |
Siteone Therapeutics, Inc. |
10',11'-modified saxitoxins for the treatment of pain
|
EP3131914B1
(en)
|
2014-04-16 |
2023-05-10 |
Idenix Pharmaceuticals LLC |
3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
|
CA2983794A1
(en)
|
2014-04-25 |
2015-10-29 |
The Brigham And Women's Hospital, Inc. |
Methods to manipulate alpha-fetoprotein (afp)
|
JP6789117B2
(ja)
|
2014-04-25 |
2020-11-25 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. |
免疫媒介性疾患を有する対象を処置するための組成物および方法
|
WO2015168079A1
(en)
|
2014-04-29 |
2015-11-05 |
Infinity Pharmaceuticals, Inc. |
Pyrimidine or pyridine derivatives useful as pi3k inhibitors
|
RU2016148364A
(ru)
|
2014-05-12 |
2018-06-13 |
Конатус Фармасьютикалз, Инк. |
Лечение осложнений хронического заболевания печени
|
EP3142748B1
(en)
|
2014-05-15 |
2019-09-11 |
Celgene Corporation |
Use of pde4 inhibitors and combinations thereof for the treatment of cystic fibrosis
|
WO2015175956A1
(en)
|
2014-05-16 |
2015-11-19 |
Celgene Corporation |
Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
|
BR112016027096B1
(pt)
|
2014-05-19 |
2023-04-11 |
Northeastern University |
Composições farmacêuticas e compostos de receptores-alvo de serotonina e seus usos
|
WO2015176780A1
(en)
|
2014-05-23 |
2015-11-26 |
Sigmoid Pharma Limited |
Celecoxib formulations useful for treating colorectal cancer
|
JP2017516779A
(ja)
|
2014-05-28 |
2017-06-22 |
アイデニクス・ファーマシューティカルズ・エルエルシー |
癌治療のためのヌクレオシド誘導体
|
JP2017518307A
(ja)
|
2014-06-02 |
2017-07-06 |
チルドレンズ メディカル センター コーポレーション |
免疫調節のための方法および組成物
|
WO2015191900A1
(en)
|
2014-06-12 |
2015-12-17 |
Ligand Pharmaceuticals, Inc. |
Glucagon antagonists
|
WO2015195634A1
(en)
|
2014-06-17 |
2015-12-23 |
Celgne Corporation |
Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
|
US9527815B2
(en)
|
2014-06-18 |
2016-12-27 |
Biotheryx, Inc. |
Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
|
PE20170268A1
(es)
|
2014-06-19 |
2017-04-21 |
Ariad Pharma Inc |
Compuestos de heteroarilo para la inhibicion de cinasa
|
US10300042B2
(en)
|
2014-06-23 |
2019-05-28 |
Celgene Corporation |
Apremilast for the treatment of a liver disease or a liver function abnormality
|
ES2843973T3
(es)
|
2014-06-27 |
2021-07-21 |
Celgene Corp |
Composiciones y métodos para inducir cambios conformacionales en cereblon y otras ubiquitina ligasas E3
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
CN114470207B
(zh)
|
2014-08-01 |
2023-09-19 |
布里格姆及妇女医院股份有限公司 |
与肺动脉高压的治疗有关的组合物和方法
|
US10092541B2
(en)
|
2014-08-15 |
2018-10-09 |
Celgene Corporation |
Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast
|
HUE061382T2
(hu)
|
2014-08-22 |
2023-06-28 |
Celgene Corp |
Eljárás myeloma multiplex kezelésére immunomoduláló vegyületekkel, antestekkel kombinálva
|
HUE043847T2
(hu)
|
2014-08-28 |
2019-09-30 |
Halozyme Inc |
Hialuronán-lebontó enzimmel és egy immun checkpoint inhibitorral végzett kombinációs terápia
|
CA2959386C
(en)
|
2014-08-29 |
2024-06-04 |
Lee Adam Wheeler |
Methods and compositions for the treatment of cancer
|
MX2017003215A
(es)
|
2014-09-12 |
2018-01-24 |
Tobira Therapeutics Inc |
Terapia de combinacion con cenicriviroc para el tratamiento de la fibrosis.
|
SG11201701957XA
(en)
|
2014-09-15 |
2017-04-27 |
Univ California |
Nucleotide analogs
|
JP7095990B2
(ja)
|
2014-09-18 |
2022-07-05 |
シーダーズ-サイナイ メディカル センター |
線維症を治療するための組成物及び方法
|
US9708348B2
(en)
|
2014-10-03 |
2017-07-18 |
Infinity Pharmaceuticals, Inc. |
Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
|
EA201700181A1
(ru)
|
2014-10-14 |
2017-09-29 |
Галозим, Инк. |
Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
|
US10183056B2
(en)
|
2014-10-16 |
2019-01-22 |
Cleveland Biolabs, Inc. |
Methods and compositions for the treatment of radiation-related disorders
|
CN111888368B
(zh)
|
2014-10-21 |
2024-02-02 |
武田药品工业株式会社 |
5-氯-n4-[2-(二甲基磷酰基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺的晶形
|
EP3209658A1
(en)
|
2014-10-24 |
2017-08-30 |
Biogen MA Inc. |
Diterpenoid derivatives and methods of use thereof
|
ES2858517T3
(es)
|
2014-11-07 |
2021-09-30 |
Sublimity Therapeutics Ltd |
Composiciones que comprenden ciclosporina
|
TW201702218A
(zh)
|
2014-12-12 |
2017-01-16 |
美國杰克森實驗室 |
關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
|
AU2015362720B2
(en)
|
2014-12-16 |
2019-11-21 |
Celgene Corporation |
Solid forms comprising (1E, 4E)-2-amino-N,N-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo(b)azepine-4-carboxamide, compositions thereof, and uses thereof
|
AU2015369690B2
(en)
|
2014-12-23 |
2019-01-17 |
SMA Therapeutics Inc. |
3,5-diaminopyrazole kinase inhibitors
|
US9676793B2
(en)
|
2014-12-23 |
2017-06-13 |
Hoffmann-Laroche Inc. |
Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
|
AU2016206682B2
(en)
|
2015-01-14 |
2021-11-11 |
The Brigham And Women's Hospital, Inc. |
Treatment of cancer with anti-LAP monoclonal antibodies
|
MX2017009406A
(es)
|
2015-01-20 |
2018-01-18 |
Xoc Pharmaceuticals Inc |
Compuestos de tipo isoergolina y usos de estos.
|
AU2016209492B2
(en)
|
2015-01-20 |
2020-10-22 |
Xoc Pharmaceuticals, Inc |
Ergoline compounds and uses thereof
|
BR112017016973A2
(pt)
|
2015-02-09 |
2018-04-03 |
Synta Pharmaceuticals Corp. |
terapia de combinação de inibidores de hsp90 e inibidores de pd-1 para tratamento de câncer
|
CN107660207B
(zh)
|
2015-03-10 |
2020-09-29 |
罗德科技公司 |
丁丙诺啡乙酸盐及用于制备丁丙诺啡的方法
|
TW201642857A
(zh)
|
2015-04-06 |
2016-12-16 |
西建公司 |
以組合療法治療肝細胞癌
|
CN107708718B
(zh)
|
2015-04-22 |
2022-01-11 |
西达-赛奈医疗中心 |
用于治疗2型糖尿病的肠内递送的苦味寡肽
|
CA2983992A1
(en)
|
2015-04-30 |
2016-11-03 |
The Regents Of The University Of Colorado, A Body Corporate |
Polycyclic indoline and indolenine compounds
|
EP3303361A1
(en)
|
2015-05-27 |
2018-04-11 |
Idenix Pharmaceuticals LLC |
Nucleotides for the treatment of cancer
|
EP3303286B1
(en)
|
2015-06-01 |
2023-10-04 |
Cedars-Sinai Medical Center |
Compounds that bind to rela of nf-kb for use in treating cancer
|
WO2016202721A1
(en)
|
2015-06-16 |
2016-12-22 |
F. Hoffmann-La Roche Ag |
Salts of (s)-4-[(r)-6-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-3,6- dihydro-pyrimidin-4-ylmethyl]-morpholine-3-carboxylic acid, salt former and methods for preparing and using the same
|
AU2016282790B9
(en)
|
2015-06-23 |
2020-01-30 |
Neurocrine Biosciences, Inc. |
VMAT2 inhibitors for treating neurological diseases or disorders
|
EP3313818B1
(en)
|
2015-06-26 |
2023-11-08 |
Celgene Corporation |
Methods for the treatment of kaposi's sarcoma or kshv-induced lymphoma using immunomodulatory compounds, and uses of biomarkers
|
KR20180023968A
(ko)
|
2015-07-02 |
2018-03-07 |
셀진 코포레이션 |
혈액암 및 충실성 종양의 치료를 위한 병용 요법
|
JP2018528260A
(ja)
|
2015-07-28 |
2018-09-27 |
ビオーム バイオサイエンシズ プライベート リミティド |
抗菌性治療薬及び予防薬
|
US10383831B2
(en)
|
2015-08-03 |
2019-08-20 |
Temple University—Of the Commonwealth System of Higher Education |
2,4,6-trialkoxystryl aryl sulfones, sulfonamides and carboxamides, and methods of preparation and use
|
SG10202101740QA
(en)
|
2015-08-17 |
2021-04-29 |
Kura Oncology Inc |
Methods of treating cancer patients with farnesyl transferase inhibitors
|
US10704035B2
(en)
|
2015-08-27 |
2020-07-07 |
President And Fellows Of Harvard College |
Compositions and methods for treatment of pain
|
WO2017044807A2
(en)
|
2015-09-09 |
2017-03-16 |
The Trustees Of Columbia University In The City Of New York |
Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
|
US10702586B2
(en)
|
2015-09-28 |
2020-07-07 |
Children's Hospital Los Angeles |
Methods for treating diseases mediated by ErbB4-positive pro-inflammatory macrophages
|
WO2017059385A1
(en)
|
2015-09-30 |
2017-04-06 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
SG10201913576RA
(en)
|
2015-10-01 |
2020-02-27 |
Heat Biologics Inc |
Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
|
WO2017069958A2
(en)
|
2015-10-09 |
2017-04-27 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
WO2017064657A1
(en)
|
2015-10-16 |
2017-04-20 |
Invictus Oncology Pvt. Ltd. |
Fluorescent anticancer platinum drugs
|
ES2972600T3
(es)
|
2015-10-30 |
2024-06-13 |
Neurocrine Biosciences Inc |
Sales de diclorhidrato de valbenazina y polimorfos de las mismas
|
WO2017079566A1
(en)
|
2015-11-05 |
2017-05-11 |
Conatus Pharmaceuticals, Inc. |
Caspase inhibitors for use in the treatment of liver cancer
|
EP3371311B1
(en)
|
2015-11-06 |
2021-07-21 |
Orionis Biosciences BV |
Bi-functional chimeric proteins and uses thereof
|
WO2017083348A1
(en)
|
2015-11-11 |
2017-05-18 |
Celgene Corporation |
Controlled release oral dosage forms of poorly soluble drugs and uses thereof
|
US10112924B2
(en)
|
2015-12-02 |
2018-10-30 |
Astraea Therapeutics, Inc. |
Piperdinyl nociceptin receptor compounds
|
EP3394057B1
(en)
|
2015-12-23 |
2022-03-30 |
Neurocrine Biosciences, Inc. |
Synthetic method for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1,-a]lsoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
|
US10830762B2
(en)
|
2015-12-28 |
2020-11-10 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
|
CN108697663A
(zh)
|
2015-12-31 |
2018-10-23 |
科内图斯医药公司 |
在肝病治疗中使用胱天蛋白酶抑制剂的方法
|
HUE051231T2
(hu)
|
2016-01-08 |
2021-03-01 |
Celgene Corp |
Antiproliferatív vegyületek, és ezek gyógyszerészeti összetételei és alkalmazásai
|
CN108712904B
(zh)
|
2016-01-08 |
2022-08-02 |
细胞基因公司 |
2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺的固体形式以及其药物组合物和用途
|
KR20180095094A
(ko)
|
2016-01-08 |
2018-08-24 |
셀진 코포레이션 |
암을 치료하기 위한 방법 및 치료요법에 대한 임상 감수성의 예측변수로서 바이오마커의 용도
|
WO2017134305A1
(en)
|
2016-02-05 |
2017-08-10 |
Orionis Biosciences Nv |
Bispecific signaling agents and uses thereof
|
JP2019507181A
(ja)
|
2016-03-04 |
2019-03-14 |
チャールストン ラボラトリーズ,インコーポレイテッド |
医薬組成物
|
EP3426278B1
(en)
|
2016-03-07 |
2024-01-03 |
Vib Vzw |
Cd20 binding single domain antibodies
|
WO2017161116A1
(en)
|
2016-03-17 |
2017-09-21 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
|
WO2017180589A1
(en)
|
2016-04-11 |
2017-10-19 |
Auspex Pharmaceuticals, Inc. |
Deuterated ketamine derivatives
|
WO2017180794A1
(en)
|
2016-04-13 |
2017-10-19 |
Skyline Antiinfectives, Inc. |
Deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams
|
US20190119758A1
(en)
|
2016-04-22 |
2019-04-25 |
Kura Oncology, Inc. |
Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
|
AU2017258781C1
(en)
|
2016-04-29 |
2022-03-03 |
Fgh Biotech, Inc. |
Di-substituted pyrazole compounds for the treatment of diseases
|
CN109071518A
(zh)
|
2016-05-04 |
2018-12-21 |
普渡制药公司 |
噁唑啉假二聚体、药物组合物及其用途
|
JP7105200B2
(ja)
|
2016-05-13 |
2022-07-22 |
オリオニス バイオサイエンシズ ビーブイ |
標的突然変異体インターフェロン-ベータおよびその使用
|
CA3023881A1
(en)
|
2016-05-13 |
2017-11-16 |
Orionis Biosciences Nv |
Therapeutic targeting of non-cellular structures
|
TWI753910B
(zh)
|
2016-05-16 |
2022-02-01 |
美商拜歐斯瑞克斯公司 |
吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
|
US10919914B2
(en)
|
2016-06-08 |
2021-02-16 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
DK3484475T3
(da)
|
2016-07-18 |
2023-11-27 |
Pharmena S A |
1-methylnicotinamid til behandlingen af kardiovaskulær sygdom
|
JOP20190008A1
(ar)
|
2016-07-26 |
2019-01-24 |
Purdue Pharma Lp |
علاج ومنع اضطرابات النوم
|
MA45857A
(fr)
|
2016-07-29 |
2021-05-19 |
Sunovion Pharmaceuticals Inc |
Composés et compositions, et utilisations associées
|
EP3490607A4
(en)
|
2016-07-29 |
2020-04-08 |
Sunovion Pharmaceuticals Inc. |
COMPOUNDS AND COMPOSITIONS, AND USES THEREOF
|
MX2019002607A
(es)
|
2016-09-07 |
2019-09-18 |
Univ Temple |
Composiciones y metodos para el tratamiento de resistencia a la insulina.
|
WO2018049080A1
(en)
|
2016-09-07 |
2018-03-15 |
Fgh Biotech, Inc. |
Di-substituted pyrazole compounds for the treatment of diseases
|
BR112019005337A2
(pt)
|
2016-09-19 |
2019-08-27 |
Mei Pharma Inc |
terapia combinada
|
WO2018067991A1
(en)
|
2016-10-07 |
2018-04-12 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
WO2018069312A1
(en)
|
2016-10-11 |
2018-04-19 |
Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne) |
Treatment of synucleinopathies
|
WO2018071814A1
(en)
|
2016-10-14 |
2018-04-19 |
The Trustees Of Columbia University In The City Of New York |
Methods of treating alcohol abuse disorder
|
CN110087649B
(zh)
|
2016-10-21 |
2022-02-18 |
西达赛奈医疗中心 |
用辛伐他汀和化疗药物与七甲川花菁染料偶联体提高肿瘤对激素拮抗剂和药物的敏感性
|
CA3040802A1
(en)
|
2016-10-24 |
2018-05-03 |
Orionis Biosciences Nv |
Targeted mutant interferon-gamma and uses thereof
|
WO2018144088A1
(en)
|
2016-11-03 |
2018-08-09 |
Alexander Vuckovic, M.D., Llc |
Compositions and methods for treating depression
|
JP2019534290A
(ja)
|
2016-11-03 |
2019-11-28 |
クラ オンコロジー, インコーポレイテッド |
癌の治療方法において使用するためのファルネシルトランスフェラーゼ阻害剤
|
WO2018089692A1
(en)
|
2016-11-09 |
2018-05-17 |
Phloronol, Inc. |
Eckol derivatives, methods of synthesis and uses thereof
|
CN110167542A
(zh)
|
2016-11-09 |
2019-08-23 |
诺沃梅迪科斯有限公司 |
1,1-二甲双胍的亚硝酸盐、药物组合物和使用方法
|
US10799503B2
(en)
|
2016-12-01 |
2020-10-13 |
Ignyta, Inc. |
Methods for the treatment of cancer
|
US20200078352A1
(en)
|
2016-12-02 |
2020-03-12 |
Neurocrine Biosciences, Inc. |
Use of Valbenazine for Treating Schizophrenia or Schizoaffective Disorder
|
CN110769826A
(zh)
|
2017-01-27 |
2020-02-07 |
纽罗克里生物科学有限公司 |
施用某些vmat2抑制剂的方法
|
WO2018140671A1
(en)
|
2017-01-27 |
2018-08-02 |
Celgene Corporation |
3-(1-oxo-4-((4-((3-oxomorpholino) methyl)benzyl)oxy)isoindolin-2-yl)piperidine-2,6-dione and isotopologues thereof
|
MX2019009255A
(es)
|
2017-02-06 |
2019-11-05 |
Orionis Biosciences Nv |
Proteínas quiméricas dirigidas y sus usos.
|
BR112019015487A2
(pt)
|
2017-02-06 |
2020-03-31 |
Spero Therapeutics, Inc. |
Formas cristalinas de tebipenem pivoxil, composições incluindo as mesmas, métodos de fabricação e métodos de uso
|
JP2020505955A
(ja)
|
2017-02-06 |
2020-02-27 |
オリオンズ バイオサイエンス インコーポレイテッド |
標的化改変型インターフェロン及びその使用
|
WO2018146074A1
(en)
|
2017-02-07 |
2018-08-16 |
Vib Vzw |
Immune-cell targeted bispecific chimeric proteins and uses thereof
|
CN116808023A
(zh)
|
2017-02-16 |
2023-09-29 |
桑诺维恩药品公司 |
治疗精神分裂症的方法
|
EP3432883B1
(en)
|
2017-02-21 |
2021-07-28 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
US10137121B2
(en)
|
2017-02-21 |
2018-11-27 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
WO2018157163A1
(en)
|
2017-02-27 |
2018-08-30 |
Shattuck Labs, Inc. |
Vsig8-based chimeric proteins
|
WO2018164996A1
(en)
|
2017-03-06 |
2018-09-13 |
Neurocrine Biosciences, Inc. |
Dosing regimen for valbenazine
|
US20180258064A1
(en)
|
2017-03-07 |
2018-09-13 |
Celgene Corporation |
Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
|
WO2018175324A1
(en)
|
2017-03-20 |
2018-09-27 |
The Broad Institute, Inc. |
Compounds and methods for regulating insulin secretion
|
CA3050086A1
(en)
|
2017-03-26 |
2018-10-04 |
Mapi Pharma Ltd. |
Glatiramer depot systems for treating progressive forms of multiple sclerosis
|
AU2018246138A1
(en)
|
2017-03-27 |
2019-08-29 |
The Regents Of The University Of California |
Compositions and method of treating cancer
|
CA3058214A1
(en)
|
2017-03-29 |
2018-10-04 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
CN110914276A
(zh)
|
2017-03-29 |
2020-03-24 |
赛特温治疗公司 |
用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物
|
WO2018200605A1
(en)
|
2017-04-26 |
2018-11-01 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating levodopa-induced dyskinesia
|
JOP20190219A1
(ar)
|
2017-05-09 |
2019-09-22 |
Cardix Therapeutics LLC |
تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
|
US10085999B1
(en)
|
2017-05-10 |
2018-10-02 |
Arixa Pharmaceuticals, Inc. |
Beta-lactamase inhibitors and uses thereof
|
US11161845B2
(en)
|
2017-05-19 |
2021-11-02 |
Nflection Therapeutics, Inc. |
Pyrrolopyridine-aniline compounds for treatment of dermal disorders
|
MA49140A
(fr)
|
2017-05-19 |
2020-03-25 |
Nflection Therapeutics Inc |
Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques
|
US20200155526A1
(en)
|
2017-05-31 |
2020-05-21 |
The Children's Medical Center Corporation |
Targeting lysine demethylases (kdms) as a therapeutic strategy for diffuse large b-cell lymphoma
|
AU2018275873A1
(en)
|
2017-06-01 |
2019-12-19 |
Xoc Pharmaceuticals, Inc. |
Ergoline derivatives for use in medicine
|
WO2018236873A1
(en)
|
2017-06-19 |
2018-12-27 |
President And Fellows Of Harvard College |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIAL INFECTION
|
WO2019005874A1
(en)
|
2017-06-26 |
2019-01-03 |
The Trustees Of Columbia University In The City Of New York |
CHOLINERGIC AGONISM FOR THE TREATMENT OF PANCREATIC CANCER
|
EP3652318A1
(en)
|
2017-07-11 |
2020-05-20 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
CA3069462A1
(en)
|
2017-07-16 |
2019-01-24 |
Neuere, Llc |
Ambroxol to improve and/or extend healthspan, lifespan and/or mental acuity
|
JP7191085B2
(ja)
|
2017-08-02 |
2022-12-16 |
サノビオン ファーマシューティカルズ インク |
イソクロマン化合物およびその使用
|
US10806730B2
(en)
|
2017-08-07 |
2020-10-20 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
MY200746A
(en)
|
2017-08-07 |
2024-01-13 |
Kura Oncology Inc |
Methods of treating cancer with farnesyltransferase inhibitors
|
MA50175A
(fr)
|
2017-09-21 |
2021-04-21 |
Neurocrine Biosciences Inc |
Formulation de valbenazine à dosage élevé et compositions, procédés et kits associés
|
US10993941B2
(en)
|
2017-10-10 |
2021-05-04 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
CN111836543A
(zh)
|
2017-10-10 |
2020-10-27 |
纽罗克里生物科学有限公司 |
施用某些vmat2抑制剂的方法
|
EP3713916A1
(en)
|
2017-11-20 |
2020-09-30 |
Kiakos, Konstantinos |
3,5-diarylidenyl-n-substituted-piperid-4-one-derived inhibitors of stat3 pathway acitivty and uses therof
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
WO2019118984A2
(en)
|
2017-12-15 |
2019-06-20 |
Solarea Bio, Inc. |
Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
|
US11708335B2
(en)
|
2017-12-18 |
2023-07-25 |
Sterngreene, Inc. |
Pyrimidine compounds useful as tyrosine kinase inhibitors
|
US20190210973A1
(en)
|
2018-01-05 |
2019-07-11 |
The Curators Of The University Of Missouri |
Compounds and methods for treatment of cystic fibrosis
|
WO2019139871A1
(en)
|
2018-01-10 |
2019-07-18 |
Cura Therapeutics Llc |
Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
|
AU2019207491A1
(en)
|
2018-01-10 |
2020-07-30 |
Cura Therapeutics, Llc |
Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
|
AU2019212435B2
(en)
|
2018-01-24 |
2022-03-10 |
Purdue Pharma L. P. |
Sleep disorder treatment and prevention
|
MX2020008208A
(es)
|
2018-02-05 |
2020-11-09 |
Orionis Biosciences Inc |
Agentes de unión a fibroblastos y uso de estos.
|
WO2019156565A1
(en)
|
2018-02-12 |
2019-08-15 |
Fast Forward Pharmaceuticals B.V. |
Improved antagonistic anti-human cd40 monoclonal antibodies
|
WO2019161236A1
(en)
|
2018-02-16 |
2019-08-22 |
Sunovion Pharmaceuticals Inc. |
Methods of treating social function disorders
|
BR112020016256A2
(pt)
|
2018-02-21 |
2020-12-15 |
AI Therapeutics, Inc. |
Terapia de combinação com apilimod e agentes gluta-matérgicos
|
US20210015899A1
(en)
|
2018-03-22 |
2021-01-21 |
The Children's Medical Center Corporation |
Methods and compositions relating to lung repair
|
WO2019222435A1
(en)
|
2018-05-16 |
2019-11-21 |
Halozyme, Inc. |
Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
|
MX2020013004A
(es)
|
2018-06-14 |
2021-02-17 |
Neurocrine Biosciences Inc |
Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.
|
EP3814327A1
(en)
|
2018-06-29 |
2021-05-05 |
Histogen, Inc. |
(s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
|
SG11202100023XA
(en)
|
2018-07-11 |
2021-01-28 |
Actym Therapeutics Inc |
Engineered immunostimulatory bacterial strains and uses thereof
|
AU2019322863A1
(en)
|
2018-08-15 |
2021-03-11 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
EP3844276A2
(en)
|
2018-08-28 |
2021-07-07 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
WO2020047328A1
(en)
|
2018-08-29 |
2020-03-05 |
Shattuck Labs, Inc. |
Combination therapies comprising pd-1-based chimeric proteins
|
US11980647B2
(en)
|
2018-09-05 |
2024-05-14 |
Solarea Bio, Inc. |
Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
|
EP3846830A4
(en)
|
2018-09-05 |
2022-07-06 |
Solarea Bio, Inc. |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF MUSCULOSKELETAL DISEASES
|
WO2020072835A1
(en)
|
2018-10-03 |
2020-04-09 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
CA3117968A1
(en)
|
2018-11-01 |
2020-05-07 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
WO2020102454A1
(en)
|
2018-11-13 |
2020-05-22 |
Regents Of The University Of Minnesota |
Cd40 targeted peptides and uses thereof
|
WO2020106303A1
(en)
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers
|
EP3883554A4
(en)
|
2018-11-20 |
2022-11-23 |
NFlection Therapeutics, Inc. |
ARYL ANILINE AND HETEROARYL ANILINE COMPOUNDS FOR THE TREATMENT OF NEGAL MARKS
|
WO2020106306A1
(en)
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Cyanoaryl-aniline compounds for treatment of dermal disorders
|
JP7393808B2
(ja)
|
2018-11-20 |
2023-12-07 |
エヌフレクション セラピューティクス インコーポレイテッド |
皮膚障害の処置のためのナフチリジノン-アニリン化合物
|
WO2020132071A1
(en)
|
2018-12-19 |
2020-06-25 |
Shy Therapeutics. Llc |
Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and f1brotic disease
|
SG11202106599WA
(en)
|
2018-12-21 |
2021-07-29 |
Kura Oncology Inc |
Therapies for squamous cell carcinomas
|
WO2020132700A1
(en)
|
2018-12-21 |
2020-06-25 |
Fgh Biotech Inc. |
Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
|
US11447468B2
(en)
|
2019-02-06 |
2022-09-20 |
Dice Alpha, Inc. |
IL-17 ligands and uses thereof
|
CA3176660A1
(en)
|
2019-02-27 |
2020-09-03 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
|
US20220142983A1
(en)
|
2019-03-01 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
TW202100506A
(zh)
|
2019-03-07 |
2021-01-01 |
美商柯納特斯製藥公司 |
半胱天冬酶(caspase)抑制劑及其使用方法
|
EP3938045A1
(en)
|
2019-03-14 |
2022-01-19 |
Sunovion Pharmaceuticals Inc. |
Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
|
TW202108170A
(zh)
|
2019-03-15 |
2021-03-01 |
美商庫拉腫瘤技術股份有限公司 |
以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症患者之方法
|
EP3712127A1
(en)
|
2019-03-22 |
2020-09-23 |
Deutsches Krebsforschungszentrum |
Novel inhibitors of histone deacetylase 10
|
US20220151962A1
(en)
|
2019-03-22 |
2022-05-19 |
Deutsches Krebsforschungszentrum |
Novel inhibitors of histone deacetylase 10
|
SG11202110472WA
(en)
|
2019-03-29 |
2021-10-28 |
Kura Oncology Inc |
Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
|
TW202102218A
(zh)
|
2019-04-01 |
2021-01-16 |
美商庫拉腫瘤技術股份有限公司 |
以法呢基(farnesyl)轉移酶抑制劑治療癌症的方法
|
KR20220004066A
(ko)
|
2019-04-03 |
2022-01-11 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
약물 전달용 이온성 액체
|
WO2020223583A1
(en)
|
2019-05-02 |
2020-11-05 |
Kura Oncology, Inc. |
Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
|
EP3978076A4
(en)
|
2019-06-03 |
2023-02-22 |
Irimajiri Therapeutics Inc. |
CYCLIC AMIDE COMPOUNDS FOR THE TREATMENT OF RABIES AND METHOD THEREOF
|
WO2020257722A2
(en)
|
2019-06-19 |
2020-12-24 |
Solarea Bio, Inc. |
Microbial compositions and methods for producing upgraded probiotic assemblages
|
WO2021007474A1
(en)
|
2019-07-11 |
2021-01-14 |
Cura Therapeutics, Llc |
Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
|
EP3997068A1
(en)
|
2019-07-11 |
2022-05-18 |
Cura Therapeutics, LLC |
Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
|
WO2021021563A1
(en)
|
2019-07-26 |
2021-02-04 |
Espervita Therapeutics, Inc. |
Functionalized long-chain hydrocarbon mono- and di-carboxylic acids useful for the prevention or treatment of disease
|
US11654124B2
(en)
|
2019-07-29 |
2023-05-23 |
Amneal Pharmaceuticals Llc |
Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
|
US10792262B1
(en)
|
2019-07-29 |
2020-10-06 |
Saol International Limited |
Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
CA3152665A1
(en)
|
2019-08-27 |
2021-03-04 |
Tonix Pharma Limited |
Modified tff2 polypeptides
|
MX2022003166A
(es)
|
2019-09-16 |
2022-06-29 |
Dice Alpha Inc |
Moduladores de il-17a y usos de los mismos.
|
WO2021059023A1
(en)
|
2019-09-26 |
2021-04-01 |
Abionyx Pharma Sa |
Compounds useful for treating liver diseases
|
KR20220091488A
(ko)
|
2019-10-01 |
2022-06-30 |
몰레큘러 스킨 테라퓨틱스, 인코포레이티드 |
Klk5/7 이중 억제제로서의 벤족사지논 화합물
|
EP4058578A2
(en)
|
2019-11-12 |
2022-09-21 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products
|
AU2020388387A1
(en)
|
2019-11-22 |
2022-06-02 |
President And Fellows Of Harvard College |
Ionic liquids for drug delivery
|
WO2021113212A1
(en)
|
2019-12-02 |
2021-06-10 |
Celgene Corporation |
Therapy for the treatment of cancer
|
WO2021183318A2
(en)
|
2020-03-09 |
2021-09-16 |
President And Fellows Of Harvard College |
Methods and compositions relating to improved combination therapies
|
TW202206062A
(zh)
|
2020-04-24 |
2022-02-16 |
美國坦普大學 高等教育聯邦系統 |
治療非酒精性脂肪肝炎的方法
|
WO2021222196A1
(en)
|
2020-04-28 |
2021-11-04 |
President And Fellows Of Harvard College |
Methods and compositions relating to ionic liquid adjuvants
|
WO2021226033A1
(en)
|
2020-05-07 |
2021-11-11 |
President And Fellows Of Harvard College |
Hyaluronic acid drug conjugates
|
EP4157923A2
(en)
|
2020-05-29 |
2023-04-05 |
President And Fellows Of Harvard College |
Living cells engineered with polyphenol-functionalized biologically active nanocomplexes
|
EP4157271A1
(en)
|
2020-05-29 |
2023-04-05 |
Boulder Bioscience LLC |
Methods for improved endovascular thrombectomy using 3,3'-diindolylmethane
|
US20230227466A1
(en)
|
2020-06-18 |
2023-07-20 |
Shy Therapeutics, Llc |
Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
US20230102840A1
(en)
|
2020-06-23 |
2023-03-30 |
President And Fellows Of Harvard College |
Compositions and methods relating to combinatorial hyaluronic acid conjugates
|
US11319313B2
(en)
|
2020-06-30 |
2022-05-03 |
Poxel Sa |
Crystalline forms of deuterium-enriched pioglitazone
|
WO2022008976A1
(en)
|
2020-07-10 |
2022-01-13 |
Institut Pasteur |
Use of gdf11 to diagnose and treat anxiety and depression
|
CA3191433A1
(en)
|
2020-08-12 |
2022-02-17 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms
|
BR112023002659A2
(pt)
|
2020-08-14 |
2023-05-02 |
Siteone Therapeutics Inc |
Inibidores de cetona não hidratados de nav1.7 para o tratamento da dor
|
US11541009B2
(en)
|
2020-09-10 |
2023-01-03 |
Curemark, Llc |
Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
|
WO2022090482A1
(en)
|
2020-10-30 |
2022-05-05 |
Ds Biopharma Limited |
Pharmaceutical compositions comprising 15-hetre and methods of use thereof
|
US20240117033A1
(en)
|
2021-01-15 |
2024-04-11 |
President And Fellows Of Harvard College |
Methods and compositions relating to anti-mfsd2a antibodies
|
EP4284394A1
(en)
|
2021-01-26 |
2023-12-06 |
Cytocares (Shanghai) Inc. |
Chimeric antigen receptor (car) constructs and nk cells expressing car constructs
|
WO2022164997A1
(en)
|
2021-01-27 |
2022-08-04 |
Shy Therapeutics, Llc |
Methods for the treatment of fibrotic disease
|
WO2022165000A1
(en)
|
2021-01-27 |
2022-08-04 |
Shy Therapeutics, Llc |
Methods for the treatment of fibrotic disease
|
WO2022187573A1
(en)
|
2021-03-05 |
2022-09-09 |
President And Fellows Of Harvard College |
Methods and compositions relating to cell membrane hybridization and camouflaging
|
WO2022189010A1
(en)
|
2021-03-07 |
2022-09-15 |
Givaudan Sa |
Methods and compositions for treating and preventing urinary tract infections
|
WO2022189856A1
(en)
|
2021-03-08 |
2022-09-15 |
Abionyx Pharma Sa |
Compounds useful for treating liver diseases
|
US20240208968A1
(en)
|
2021-03-10 |
2024-06-27 |
Dice Molecules Sv, Inc. |
Alpha v beta 6 and alpha v beta 1 integrin inhibitors and uses thereof
|
US11613561B2
(en)
|
2021-03-19 |
2023-03-28 |
Tiba Biotech, Llc |
Artificial alphavirus-derived RNA replicon expression systems
|
WO2022226166A1
(en)
|
2021-04-22 |
2022-10-27 |
Protego Biopharma, Inc. |
Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
|
EP4347568A1
(en)
|
2021-05-27 |
2024-04-10 |
Protego Biopharma, Inc. |
Heteroaryl diamide ire1/xbp1s activators
|
WO2022265880A1
(en)
|
2021-06-16 |
2022-12-22 |
President And Fellows Of Harvard College |
Improved methods and compositions for drug delivery relating to ionic liquids
|
WO2022271537A1
(en)
|
2021-06-25 |
2022-12-29 |
President And Fellows Of Harvard College |
Compositions and methods relating to injectable microemulsions
|
KR20240044458A
(ko)
|
2021-08-05 |
2024-04-04 |
브리스톨-마이어스 스큅 컴퍼니 |
Her2 억제제로서 사용하기 위한 트리시클릭 융합된 피리미딘 화합물
|
WO2023034504A1
(en)
|
2021-09-01 |
2023-03-09 |
Flagship Pioneering Innovations Vi, Llc |
Methods and compositions for inducing fetal hemoglobin, modulating erythroid cell lineages, and perturbing megakaryocyte lineages
|
US20230083717A1
(en)
|
2021-09-01 |
2023-03-16 |
Flagship Pioneering Innovations Vi, Llc |
Methods and compositions for promoting adipocyte beiging
|
WO2023034507A1
(en)
|
2021-09-01 |
2023-03-09 |
Flagship Pioneering Innovations Vi, Llc |
In vivo and ex vivo methods of modulating t cell exhaustion/de-exhaustion
|
WO2023034506A1
(en)
|
2021-09-01 |
2023-03-09 |
Flagship Pioneering Innovations Vi, Llc |
Methods and compositions for inducing fetal hemoglobin
|
WO2023039164A2
(en)
|
2021-09-09 |
2023-03-16 |
Flagship Pioneering Innovations Vi, Llc |
Methods and compositions for modulating goblet cells and for muco-obstructive diseases
|
US20230077584A1
(en)
|
2021-09-09 |
2023-03-16 |
Flagship Pioneering Innovations Vi, Llc |
Methods and compositions for modulating enteroendocrine cells
|
WO2023043827A2
(en)
|
2021-09-14 |
2023-03-23 |
Flagship Pioneering Innovations Vi, Llc |
Methods and compositions for perturbing monocyte and neutrophil lineages
|
WO2023055457A1
(en)
|
2021-09-29 |
2023-04-06 |
Amneal Pharmaceuticals Llc |
Baclofen-containing granule formulations and reduced patient exposure to metabolite variations
|
EP4162933A1
(en)
|
2021-10-08 |
2023-04-12 |
Algiax Pharmaceuticals GmbH |
Compound for treating non-alcoholic fatty liver disease and related diseases
|
WO2023059846A1
(en)
|
2021-10-08 |
2023-04-13 |
President And Fellows Of Harvard College |
Ionic liquids for drug delivery
|
CA3236150A1
(en)
|
2021-10-22 |
2023-04-27 |
Prosetta Biosciences, Inc. |
Novel host-targeted pan-respiratory antiviral small molecule therapeutics
|
CA3235692A1
(en)
|
2021-10-28 |
2023-05-04 |
Zywie, Llc |
Modified forms of ambroxol for therapeutic use
|
WO2023092150A1
(en)
|
2021-11-22 |
2023-05-25 |
Solarea Bio, Inc. |
Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
|
AU2022399572A1
(en)
|
2021-11-30 |
2024-05-02 |
Kura Oncology, Inc. |
Macrocyclic compounds having farnesyltransferase inhibitory activity
|
US20230190834A1
(en)
|
2021-12-21 |
2023-06-22 |
Solarea Bio, Inc. |
Immunomodulatory compositions comprising microbial entities
|
US11932665B2
(en)
|
2022-01-03 |
2024-03-19 |
Lilac Therapeutics, Inc. |
Cyclic thiol prodrugs
|
US11981694B2
(en)
|
2022-01-03 |
2024-05-14 |
Lilac Therapeutics, Inc. |
Acyclic thiol prodrugs
|
WO2023168426A1
(en)
|
2022-03-03 |
2023-09-07 |
Enosi Therapeutics Corporation |
Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof
|
WO2023192817A1
(en)
|
2022-03-28 |
2023-10-05 |
Isosterix, Inc. |
Inhibitors of the myst family of lysine acetyl transferases
|
WO2023192904A1
(en)
|
2022-03-30 |
2023-10-05 |
Biomarin Pharmaceutical Inc. |
Dystrophin exon skipping oligonucleotides
|
GB2619907A
(en)
|
2022-04-01 |
2023-12-27 |
Kanna Health Ltd |
Novel crystalline salt forms of mesembrine
|
WO2023201282A1
(en)
|
2022-04-14 |
2023-10-19 |
Bristol-Myers Squibb Company |
Novel gspt1 compounds and methods of use of the novel compounds
|
WO2023201348A1
(en)
|
2022-04-15 |
2023-10-19 |
Celgene Corporation |
Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma
|
WO2023211990A1
(en)
|
2022-04-25 |
2023-11-02 |
Siteone Therapeutics, Inc. |
Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
|
WO2023215781A1
(en)
|
2022-05-05 |
2023-11-09 |
Biomarin Pharmaceutical Inc. |
Method of treating duchenne muscular dystrophy
|
WO2023230524A1
(en)
|
2022-05-25 |
2023-11-30 |
Flagship Pioneering Innovations Vi, Llc |
Compositions of secretory and/or catalytic cells and methods using the same
|
US20240158370A1
(en)
|
2022-09-09 |
2024-05-16 |
Innovo Therapeutics, Inc. |
CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS
|
WO2024073473A1
(en)
|
2022-09-30 |
2024-04-04 |
Boulder Bioscience Llc |
Compositions comprising 3,3'-diindolylmethane for treating non-hemorrhagic closed head injury
|
WO2024086246A2
(en)
|
2022-10-18 |
2024-04-25 |
Eluciderm Inc. |
2-substituted 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3- djpyrimidin-4-ones for wound treatment
|
WO2024091863A1
(en)
|
2022-10-25 |
2024-05-02 |
Starrock Pharma Llc |
Combinatorial, and rotational combinatorial therapies for obesity and other diseases
|
WO2024092037A1
(en)
|
2022-10-26 |
2024-05-02 |
Protego Biopharma, Inc. |
Spirocycle containing pyridone compounds
|
US20240174695A1
(en)
|
2022-10-26 |
2024-05-30 |
Protego Biopharma, Inc. |
Spirocycle Containing Bicyclic Heteroaryl Compounds
|
WO2024092043A1
(en)
|
2022-10-26 |
2024-05-02 |
Protego Biopharma, Inc. |
Spirocycle containing pyridine compounds
|
US20240165112A1
(en)
|
2022-11-04 |
2024-05-23 |
Bristol-Myers Squibb Company |
Therapy for the treatment of cancer
|
WO2024118801A1
(en)
|
2022-11-30 |
2024-06-06 |
Protego Biopharma, Inc. |
Linear heteroaryl diamide ire1/xbp1s activators
|
WO2024118810A1
(en)
|
2022-11-30 |
2024-06-06 |
Protego Biopharma, Inc. |
Cyclic pyrazole diamide ire1/xbp1s activators
|